cms.bioaccessla.com

Tag: clinical trials

  • A Practical Regulatory Timeline For First-In-Human Medical Device Studies In Latin America (2026)

    A Practical Regulatory Timeline for First-in-Human Medical Device Studies in Latin America (2026)

    For MedTech founders and regulatory directors, Latin America can be the fastest path to a first-in-human (FIH) medical device milestone—if you treat timeline as an operational deliverable, not a hope. The region is not a single market: documentation, ethics review cadence, import steps, and contract mechanics vary by country and by whether your study is observational, non-significant risk (NSR), or significant risk.

    This article provides a practical way to plan an FIH device study timeline across Latin America in 2026: what workstreams to run in parallel, where delays typically occur, and how to de-risk your critical path without compromising compliance or participant safety.

    1) Start with a “workstream map,” not a single Gantt chart

    FIH device studies commonly stall because sponsors build one linear plan when the reality is a set of interdependent workstreams. A useful planning framework separates your launch into seven workstreams, each with its own owners, documents, and review cycles:

    • Protocol package (protocol, IB/IFU, risk analysis, monitoring plan, DSMB plan if needed)
    • Country regulatory submission (device classification/route, authority forms, translations, legalization requirements if any)
    • Ethics approval (central/local IRB/ethics committee workflow, consent language, recruitment materials)
    • Site contracting & budgets (CTA, indemnification, insurance certificates, payment triggers)
    • Import & logistics (shipping lanes, customs broker readiness, temp-control, labeling)
    • Site activation (SIV readiness, staff training, device accountability tools)
    • First patient in (FPI) (screening plan, recruitment levers, backup sites)

    When these workstreams are run deliberately in parallel, many sponsors can compress timelines materially versus the “submit, wait, then do the next thing” approach.

    2) A realistic 2026 timeline template (what to do in each month)

    Every program differs, but for early-feasibility or FIH device studies, a practical timeline template often looks like this:

    • Weeks 0–2: Feasibility + site shortlist. Confirm patient pool, investigator interest, imaging/lab capabilities, and whether your endpoints are standard-of-care in that setting.
    • Weeks 1–4: Submission-ready document set. Build the “country-ready” version of the protocol package: consistent terminology, device description aligned with IFU, and localized consent templates.
    • Weeks 3–8: Parallel ethics + regulatory preparation. Prepare authority-specific forms while the ethics packet is being finalized; do not wait for final contracts to start regulatory readiness.
    • Weeks 6–12: Contracts, budgets, and insurance. In many countries, the slow step is not scientific review but the negotiation of indemnification clauses, invoice rules, and insurance wording.
    • Weeks 8–14: Import and first shipment readiness. Align labeling, airway bills, and broker processes early; confirm whether your device is shipped as commercial goods, samples, or study materials and plan accordingly.
    • Weeks 12–18: SIV + site activation. Execute training, device accountability procedures, and data capture dry runs.
    • Weeks 16–24: FPI window. A strong screening plan and backup sites protect you from “approval achieved, recruitment delayed.”

    Rather than treating “approval” as the finish line, treat it as the midpoint: you still need operational readiness to reach FPI.

    3) Where timelines slip (and how to protect the critical path)

    Across Latin America, recurring delays tend to cluster into a few categories:

    • Translation and document consistency issues. Inconsistencies between protocol, IFU, and consent language trigger rework during ethics review.
    • Contract sequencing mistakes. If you wait for final CTA language before starting budget alignment or insurance certificates, you create avoidable idle time.
    • Import readiness left too late. Even when the device is low-risk, shipments can be rejected if labeling, documentation, or declared values are unclear.
    • Over-reliance on a single site. A single high-performing hospital is not a recruitment strategy; build a backup shortlist early.

    Two simple practices prevent many timeline slips: (1) run a weekly “document control” check to keep all versions synchronized, and (2) hold a pre-import readiness call with your broker and study team before any shipment is booked.

    4) Country selection: choose based on constraints, not hype

    Latin America offers multiple attractive options, but the best country for your FIH study depends on constraints:

    • Need speed? Prioritize clear ethics pathways, experienced investigators, and predictable import lanes for study materials.
    • Need specific patient phenotypes? Choose where that patient population is concentrated and where endpoints align with standard clinical practice.
    • Need imaging or specialized procedures? Ensure site infrastructure and maintenance/QA standards can support your device and endpoints.

    A practical rule: pick the country where your operational bottleneck is easiest to solve. If your bottleneck is import complexity, choose the market where your logistics and broker experience is strongest. If your bottleneck is investigator capability, choose the market with the deepest specialty network.

    FAQ

    • How long does an FIH device study typically take to reach first patient in (FPI) in Latin America?
      Many sponsors plan a 4–6 month window from kick-off to FPI when workstreams run in parallel, but timelines depend on device risk, required reviews, contracting speed, and import readiness.
    • What is the most common avoidable delay?
      Contracting and insurance language misalignment, followed closely by late import readiness and inconsistent translated documents.
    • How can sponsors reduce timeline risk without cutting corners?
      Use a workstream map, keep document versions synchronized, and build redundancy (backup sites, backup shipping lanes, and a recruitment contingency plan).

    Bottom line: In 2026, sponsors that treat Latin America FIH timelines as an integrated regulatory-and-operations program—rather than a single “submission” event—can reach FPI faster and with fewer surprises.

  • Brazil’s 90 Day Clinical Trial Review Cap: What Medtech Sponsors Should Do Before Submitting

    Brazil’s 90-Day Clinical Trial Review Cap: What MedTech Sponsors Should Do Before Submitting

    Brazil has moved from being a “high-potential but unpredictable” country for early-stage MedTech studies to a jurisdiction with a defined statutory review clock. For sponsors, that shift is not just a speed story — it is a planning story. When review timelines become shorter and more predictable, the relative impact of preventable sponsor-side errors gets larger.

    This article is written for MedTech founders, clinical operations leaders, and regulatory directors who want to run first-in-human (FIH) or early feasibility work in Brazil without losing weeks to rework. We focus on what you can control before submission: dossier readiness, ethics strategy, local operational prerequisites, and vendor orchestration.

    Why a faster regulatory clock changes the sponsor playbook

    Short timelines compress decision-making. If you used to “fix it after ANVISA feedback,” you may no longer have that luxury — because site contracts, import permits, radiology workflows, and ethics committee coordination can become the rate-limiting steps. A faster clock also forces clearer internal governance: who owns the final protocol, the risk assessment, the device technical file, and the country-specific annexes?

    Practically, the sponsor question becomes: How do we arrive at Day 0 with no missing pieces? The goal is to avoid pauses caused by translation gaps, document format mismatches, incomplete investigator packages, or unaligned device documentation.

    Pre-submission checklist: what to lock down before Day 0

    • Protocol version control: Confirm the final protocol, synopsis, schedule of assessments, and statistical plan are aligned — and that the same versions appear in every submission component.
    • Risk classification and device description: Ensure the device description, intended use, instructions for use, and risk analysis are consistent across documents. Inconsistency is one of the most common sources of questions.
    • Investigator and site packages: Collect CVs, training evidence, GCP documentation, and site capabilities early. In Brazil, the operational readiness of sites can become as important as the regulatory dossier.
    • Translations and local formatting: Build time for Portuguese localization and formatting checks. A strong translation is not only linguistic — it must preserve clinical meaning and match annex references.
    • Informed consent strategy: Prepare consent language that is clear, compliant, and aligned to local norms. If your device includes software, connectivity, or data transfer, incorporate that into consent and data handling text.
    • Import and logistics planning: Map the path for device shipment, labeling, and storage. Even for non-radioactive devices, customs, temperature needs, and distribution responsibilities can derail timelines.

    Parallel ethics + regulatory review: how to operationalize it

    When a system allows parallel tracks, the bottleneck often shifts to coordination. Sponsors should treat ethics submission as a project with its own critical path, not as an administrative afterthought. Build a unified submission calendar and align on:

    • Sequence of internal approvals: Decide who signs off on ethics content and who owns final responses.
    • Site-by-site variance: Even with a national framework, each site can introduce operational nuance. Standardize as much as possible, but plan for local adjustments.
    • Response management: Pre-write response templates for common questions (risk/benefit, recruitment strategy, device safety, data management) so you can move quickly.

    For FIH and early-stage work, ethics committees will often focus on patient protection and feasibility: training, emergency procedures, follow-up, and the practical ability of the site to manage adverse events. Your dossier should show readiness, not just compliance.

    What MedTech sponsors often underestimate in Brazil

    Speed-friendly frameworks do not eliminate complexity; they amplify the cost of under-planning. The most common underestimates include:

    • Data and privacy workflows: If your study uses digital endpoints or remote monitoring, align data flows, storage, and access controls early.
    • Device accountability: Plan how devices will be tracked, stored, returned, and reconciled. Accountability gaps create audit risk and can slow activation.
    • Training: Documented training is not optional in early-stage device studies. Build training into your timeline and capture evidence systematically.
    • Vendor interdependencies: CRO, imaging core lab, shipping/logistics, and local regulatory support must operate from the same timeline assumptions and document set.

    FAQ

    1) Does a statutory review cap guarantee approval in 90 days?
    No. A cap can improve predictability, but the practical timeline still depends on dossier quality, completeness, and how quickly questions are resolved.

    2) Should we treat Brazil as a first-choice country for FIH studies?
    Brazil can be compelling when the patient population, investigator expertise, and activation path fit the product. Sponsors should evaluate Brazil alongside other Latin American jurisdictions based on feasibility, ethics speed, and operational readiness.

    3) What’s the biggest sponsor-side mistake?
    Submitting with misaligned documents (protocol vs. device description vs. risk file) and assuming issues can be fixed “during review.” In faster systems, that approach often costs more time, not less.

    Bottom line: If your goal is to capture the benefit of a faster review framework, your work starts well before Day 0. A sponsor-side checklist — executed early — is often the difference between a fast approval and a slow cycle of preventable questions.

  • $8 Billion Of Pharma Capital Just Pointed At Argentina. What Medtech Founders Should Take From The May 29 CAEME Announcement.

    On May 29, 2026, the Cámara Argentina de Especialidades Medicinales (CAEME) announced jointly with President Javier Milei a six-year clinical research investment commitment from seven multinational pharmaceutical companies: Pfizer, Merck, Roche, Novartis, BMS, GSK, and Sanofi. The total commitment is USD 8 billion through 2032. On the same week, ANMAT’s Disposición 2978/2026, which cut import tariffs on medicines and medical devices by 50 to 70 percent, came into operative effect on June 1.

    For a Latin American clinical research operator that has spent 16 years arguing the case to MedTech and biotech founders, the May 29 to June 1 sequence is the strongest sovereign-level signal a Latin American country has produced for clinical research in the past decade. The data and the policy arrived in the same week. The Big Pharma capital and the regulator’s tariff cut arrived in the same week. The case Argentina has been building since Disposición 7516/25 first came into force in 2025 is now publicly endorsed by both seven multinational CEO offices and the federal executive.

    The interesting question is not whether founders should use Argentina for first-in-human (FIH) work. The interesting question is what happens to the Argentine clinical research ecosystem when USD 8 billion of pharma capital flows into a site base that, in 2026, has only 80 to 120 actively credentialed Phase 1/2 sites. This post unpacks the saturation thesis and what early-stage MedTech founders should be doing about it in 2026.

    The Site Saturation Math

    The CAEME pledge of USD 8 billion over 2026 to 2032 implies an average commitment of approximately USD 1.33 billion per year. At industry-average sponsored Phase 1 through 3 trial costs of USD 1 to 3 million per site per year for clinical operations and site fees, the pledge fully funds roughly 430 to 1,330 new trial-site-years annually if disbursed at the announced pace.

    Argentine clinical research currently runs at roughly 290 ANMAT-authorized trials per year (2025 throughput), with 1,188 active studies under ANMAT supervision and approximately 80 to 120 actively credentialed Phase 1/2 sites across all therapeutic areas. The pledge contemplates a 2.5x step-up in trial inflows against approximately the same site base.

    The implication is straightforward. By 2027, Argentine Phase 1/2 site capacity becomes the binding constraint on the system. Regulator throughput, which is already operative at 62 calendar days under Disposición 7516/25, is no longer the rate-limiting step. Site availability is. And site availability at top investigators compresses asymmetrically. A senior PI running three trials in 2026 does not move to six trials in 2027. A senior PI running three trials moves to four trials, while the marginal Phase 1/2 site backlog elongates by 6 to 12 months for the founders arriving last.

    Founders who lock in Argentine site relationships in 2026 are locking in the top quartile of investigators. Founders who arrive in 2027 are competing for what is left after Pfizer, Novartis, and the other CAEME signatories have claimed the senior beds.

    Why the Argentine Government Did This Now

    Three forces converged in 2026 that made the May 29 to June 1 sequence possible. First, the Milei administration’s broader productivity and quality agenda, codified in the proposed PCT (Productividad, Calidad y Transparencia) bill, created the legislative context for industry investment commitments. Second, ANMAT’s operational reform sequence, beginning with Disposición 7516/25 (62-day pathway, parallel ethics plus agency review, ICH E6(R3) alignment), reached a level of regulator credibility that multinationals could underwrite. Third, the comparative landscape moved against Argentina’s peer regulators. Colombia’s Ley 191 stalled in Comisión Séptima and is now effectively dead this term. Brazil’s ICH E6(R3) adoption remains on a slower trajectory than ANVISA’s 2024-2025 board sessions suggested. Mexico’s 30-day target announced at AMIIF on May 19 lacks DOF formalization. Argentina is the only major LATAM jurisdiction in 2026 with operative regulatory reform, operative tariff policy, and operative sovereign-level industry commitment in the same week.

    The PCT bill is the only caveat that matters. The CAEME pledge is contingent on PCT passage. As of June 1, the bill remains stalled. Founders evaluating Argentine sites should treat the regulatory and tariff case as the base case and the CAEME pledge as additive upside. Disposición 7516/25 and Disposición 2978/2026 are in force regardless.

    How to Sequence Argentina in 2026

    The country sequencing decision a MedTech founder makes in 2026 is structurally different than the same decision in 2024. Two years ago, the case for Argentine FIH rested on cost (USD 15,000 to 35,000 per patient versus USD 40,000 to 75,000 in the U.S. and Europe) and regulator throughput (62 days under 7516/25 versus 120 to 180 days under FDA EFS). Both arguments still apply, and the Disposición 2978/2026 tariff cut now removes a 4 to 8 percent additional cost layer on imported devices and study drugs.

    What is new in 2026 is the time pressure. The CAEME pledge does not change the operational case. It changes the urgency of the operational case. A founder who has been considering Argentine site selection for the past six months and has not yet executed is, beginning June 1, 2026, on the wrong side of a closing window. By Q4 2026, the same site relationships will be visibly competitive. By Q2 2027, the top-quartile PI list will be substantively claimed.

    For structural heart and cardiovascular device programs, the recommended sequence is Argentine site selection initiated by Q3 2026, ANMAT protocol filing by Q4 2026, first patient enrolled in Q1 2027. This sequence preserves access to the InCor São Paulo, Hospital Italiano Buenos Aires, and Fundación Cardiovascular Bogotá tier of cardiovascular research centers, with the Argentine arm operating in parallel with a U.S. EFS submission.

    For neuromodulation programs, the recommended sequence compresses further. Site selection at seed close (or post-Series A), ANMAT protocol filing within 90 days of site lock-in. The neuromodulation patient base in Argentina is concentrated at fewer specialized institutions than cardiovascular work, and the saturation pressure on neuromodulation-credentialed PIs is therefore more acute. Founders who have not selected Argentine neuromodulation sites by end of 2026 will likely face 6 to 9 month delays in 2027.

    For radiopharmaceutical and theranostics programs, the operational sequence is different in kind. Site selection has to be scoped before ANY other operational step because of isotope logistics, central pharmacy capacity, and credentialed nuclear medicine institutions. Radiopharma founders who wait until post-acceleration or post-Series A to scope LATAM partners have already added 6 to 9 months to their pivotal timeline. The Argentine radiopharma site base is even more concentrated than the neuromodulation base, and the CAEME pledge is highly likely to direct radiopharma-adjacent investment into the same handful of credentialed institutions.

    What This Means for the Colombia Case

    For bioaccess® and for any founder using a LATAM CRO with Colombian site depth, the May 29 to June 1 sequence forces an honest reassessment. Colombia in 2026 holds the following: established U.S.-trained PI density at specific institutions (Fundación Cardioinfantil, Fundación Valle del Lili, Universidad Javeriana), strong therapeutic-area depth in cardiovascular and oncology, INVIMA throughput at roughly 90 to 120 days. Colombia does not hold: operative sovereign-level investment commitment, modern ICH E6(R3) framework alignment (Resolución 8430/1993 remains the operative framework), or a recent tariff reduction comparable to Disposición 2978/2026.

    The Colombia case for 2026 is no longer “cheaper and faster.” The Colombia case is “specific therapeutic-area depth, U.S.-trained PI networks, and complementarity to an Argentine arm.” For founders running cardiovascular or oncology programs requiring U.S. data acceptance under FDA IDE pathways, the Colombian PI base remains uniquely qualified. For founders running neuromodulation or radiopharmaceutical programs at the FIH stage, the Argentine arm is now the primary recommendation, with Colombian sites operating as the complementary geography rather than the primary geography.

    This is a more nuanced positioning than the one bioaccess® and other LATAM CROs have historically used. It is also the positioning that will hold up over the next 12 to 18 months as the Argentine site saturation pressure builds.

    What Founders Should Do Before End of Q3 2026

    For MedTech, biotech, and radiopharma founders who have not yet scoped their LATAM site portfolio, the practical sequence over the next 90 days looks like:

    First, identify whether the program’s FIH country sequence is Argentina-primary, Argentina-secondary, or Argentina-complementary based on therapeutic area, regulatory pathway, and capital constraints. For structural heart and cardiac ablation, Argentina-primary or Argentina-secondary makes sense. For neuromodulation, Argentina-primary. For radiopharma, Argentina-primary with explicit isotope logistics scoping. For oncology devices with U.S. IDE pathway requirements, Argentina-complementary alongside Colombia or Brazil.

    Second, scope site availability at the institutions most likely to be impacted by the CAEME pledge. The largest pharma signatories (Pfizer, Roche, Novartis) historically work with a specific set of Argentine investigators in cardiology, oncology, and metabolism. Site availability at those investigators will compress first.

    Third, file ANMAT protocols on the Disposición 7516/25 parallel-review pathway. The 62-day timeline allows a 2026 Q3 site selection to produce first-patient-in by year-end. Delays beyond Q3 begin pushing first-patient-in into Q2 2027, by which point the competitive pressure on senior PIs will be visible in enrollment delays.

    Fourth, consider the Disposición 2978/2026 tariff cut as a planning input. The 50 to 70 percent reduction on imported devices and study drugs is most material for early-stage MedTech programs that import 80 to 100 percent of investigational supply. Plan device manufacturing and shipment timing to maximize the tariff savings.

    The Bottom Line

    Argentina did not become a clinical research hub on May 29, 2026. Argentina has been a clinical research hub for 30 years. What happened on May 29 to June 1, 2026, is that the federal executive, the regulator, and seven multinational pharma CEOs publicly aligned on the same operational thesis in the same week. That alignment compresses the founder decision window from years to quarters.

    For early-stage MedTech, biotech, and radiopharma founders evaluating LATAM FIH strategy, the operational reality is that the next 12 to 18 months are a sponsor-favorable market with multiple jurisdictions actively recruiting trial volume. Sponsors who position now benefit from regulator attention, expedited review windows, and access to the senior PI base. Sponsors who delay lose that window.

    The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong country sequence for their specific program. Argentina’s May 29 to June 1 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 LATAM FIH country sequencing decision and want a tailored proposal that incorporates the new ANMAT regulatory and tariff environment alongside Colombian and Brazilian complementary site options, the team at bioaccess® can produce a country-level model within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Argentina Just Cut Clinical Trial Import Costs By 50 70%. Here’s What 290 Authorized Trials In 2025 Tell Founders.

    On May 19, 2026, Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT) published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026. The preamble of the instrument states the policy goal explicitly: to attract clinical trial investment to Argentina. The next day, the Argentine government released throughput data that explained why the policy was built: 290 clinical trials authorized in 2025, a 12 percent year-over-year increase, with 114 already authorized in the first quarter of 2026 and 1,188 active studies under ANMAT supervision. Argentina is now formally branding itself an “internationally competitive clinical research hub.”

    For a Latin American clinical research operator who has spent 16 years arguing the speed-and-cost case to MedTech and biopharma founders, the May 19-20 sequence is the most unusual validation event the regulatory landscape has produced this decade. Most LATAM clinical research positioning is CRO marketing. Argentina’s came from the regulator itself, in the preamble of a binding instrument, on government letterhead, with throughput numbers attached. That is not the same kind of evidence as a competitive pitch deck.

    For founders running a 10-patient first-in-human (FIH) device study, the math now stacks in a way that materially changes the country sequencing decision. This post unpacks what changed, what stayed the same, and how founders pursuing a U.S. Early Feasibility Studies (EFS) plus out-of-U.S. (OUS) FIH strategy should think about Argentina in 2026.

    What Changed on May 19, 2026

    Disposición 2978/2026 is the binding instrument. The tariff reduction applies across the import basket relevant to clinical research operations, including investigational drugs, medical devices in trial-supply quantities, reference standards, and disposable consumables tied to study protocols. The pre-existing effective duty rate for imported medical devices in Argentina ranged from 12 to 18 percent before May 19. Under the new schedule, that effective rate compresses to roughly 6 to 12 percent for trial-supply imports, with category-specific reductions ranging from 50 to 70 percent depending on the harmonized system classification.

    On its own, the tariff cut is meaningful. It is more meaningful in combination with the operational baseline Argentina already had in place. Disposición 7516/2025, which came into force in 2025 and is fully aligned with ICH E6(R3), caps clinical trial protocol authorization at 62 calendar days (45 working days maximum). That includes parallel ethics committee review and ANMAT agency review, not sequential review. For comparison, the U.S. EFS pathway typically runs 120 to 180 days from IDE submission to first patient enrolled. Argentina’s ANMAT pathway is 60 to 120 days faster, depending on the comparison case.

    The April 24, 2026 importación simplification further compresses pre-first-patient timelines by removing roughly 14 to 21 days of customs and import-classification delay that previously sat between protocol approval and the actual arrival of study material at site. The June 1, 2026 tariff reduction now removes the cost penalty that previously sat alongside that delay.

    The Throughput Number Most Founders Miss

    The 290-trials-in-2025 figure deserves more attention than it has received. Of those 290 authorizations, the regulator-reported mix is approximately 70 percent biopharma and 30 percent medical device or combination product. The Q1 2026 pace of 114 authorizations annualizes to roughly 456 trials per year, which would represent a 57 percent year-over-year acceleration if sustained. Even if the run rate moderates by half, Argentina’s 2026 throughput will exceed all prior years on record.

    For a founder evaluating site capacity risk, the 1,188 active studies under ANMAT supervision is the more strategic data point. Argentina has the patient-volume depth and the principal-investigator network density to absorb new sponsor demand without the recruitment friction that emerging-market sites with thinner trial histories often impose. A FIH MedTech sponsor running a 10-patient study at two Argentine sites can realistically expect first-patient-in within 90 days of protocol approval, and last-patient-in within 5 to 7 months of contract execution. Those numbers have been stable across the last 36 months of bioaccess® operational experience.

    The Cost Math, Refreshed

    Pre-May 19, 2026, the LATAM per-patient cost range for a FIH MedTech study sat at $15,000 to $35,000, compared to $40,000 to $75,000 in the U.S. and Europe. For a 10-patient FIH device study, that is a $250,000 to $400,000 absolute swing, sufficient on its own to fund roughly four months of clinical operations headcount or a complete adaptive design biostatistics package.

    The June 1 tariff reduction does not move the per-patient labor cost. It moves the device and drug-import cost component, which typically represents 8 to 15 percent of total study cost for a MedTech FIH trial relying on imported investigational devices. A 50 percent reduction on that line item produces a 4 to 8 percent reduction on total study cost, which compounds with the labor cost advantage Argentina already offered. On a $250,000 study, that is an additional $10,000 to $20,000 of effective savings. On a $1 million pivotal-stage Argentine arm of a multi-country trial, the effect grows proportionally.

    The strategic value is not the headline savings number. It is the regulatory clarity that the tariff cut produces. Sponsors evaluating Argentina now know that the regulator has formally committed to clinical research as a strategic policy priority. That changes how a CFO evaluates jurisdiction risk in the IND-enabling phase.

    The Database Anomaly and How to Work Around It

    One operational caveat is worth flagging directly. ANMAT’s public pharmacology database, which historically served as the citable reference for trial throughput and status, remains anchored at a September 30, 2025 data cutoff. As of the publication date of this post, that anomaly has persisted for four consecutive weekly review cycles. The most likely explanation is a backend migration tied to the broader Argentine government’s digital transformation initiative, but the database itself does not yet reflect Q4 2025 or any 2026 data.

    For sponsors building a regulatory dossier or a board pack that requires citable Argentine clinical research throughput data, the May 20, 2026 government statistics package, available through argentina.gob.ar communications channels, is now the more authoritative source than the database. For real-time individual study status, the RENIS (Registro Nacional de Investigaciones en Salud) registry, accessible through the SISA portal, remains operative and current. Disposición 7516/25, the 62-day pathway, the importación simplification, and Disposición 2978/2026 are all fully in force regardless of the database refresh status.

    How to Sequence Argentina in a U.S. EFS Plus OUS FIH Strategy

    The most common 2026 founder question is whether to run U.S. EFS first, OUS FIH first, or both in parallel. The May 19-20 Argentina updates do not change the answer in every case, but they change it in enough cases that the question is worth re-examining.

    For structural heart, neuromodulation, and radiopharmaceutical or theranostic FIH programs, where the U.S. EFS pathway involves an IDE submission with 120 to 180 day review timelines, the parallel Argentina arm is now substantially more attractive. The argument runs as follows: a sponsor who files the IDE with FDA in month one and simultaneously files the ANMAT protocol under Disposición 7516/25 will, in a typical case, have ANMAT approval and first-patient-in achieved before the FDA has finished its initial IDE review. That bridge data, if collected against an FDA-aligned endpoint set, materially strengthens the IDE review and accelerates the post-IDE clinical trial path.

    The bridge data approach assumes the sponsor designs the Argentine arm to match the FDA-expected endpoints from the outset. That is not a regulatory obligation in Argentina, but it is the operational discipline that converts a 62-day pathway into a strategic asset rather than a parallel cost center. ICH M11 CeSHarP, finalized by ICH on May 21, 2026, makes that endpoint-aligned protocol authoring substantially more efficient than it was a year ago.

    For absorbable implants, cardiac ablation, and oncology device FIH programs, the Argentina arm makes sense as the primary FIH site set, with the U.S. EFS following as a confirmatory phase rather than as the primary first-in-human exposure. The 2026 tariff reduction further tips the math in this direction for sponsors with capital constraints between Series A and Series B.

    What This Means for the Latin American Clinical Research Landscape

    Argentina’s May 19-20 sequence is the clearest example to date of a Latin American regulator choosing, in policy, to compete for clinical research investment. Brazil, Mexico, and Colombia have made similar moves in the past 24 months, but none have packaged a binding tariff reduction with a coordinated government statistics release in the same week. The combination is what makes the Argentine moment unusual.

    For Latin American CROs, the strategic implication is that the next 12 to 18 months will likely be a sponsor-favorable market, with multiple jurisdictions actively recruiting trial volume. Sponsors who position now will benefit from regulator attention, expedited review windows, and the willingness of agencies to engage with novel trial designs at the pre-submission stage. Sponsors who delay until the policy environment has fully stabilized will lose the strategic window.

    For bioaccess® and other LATAM operators, the implication is that the value proposition has moved beyond cost and speed into regulatory partnership. The conversation a founder needs to have with their CRO in 2026 is no longer about how fast the trial can run. It is about how the trial design, the country sequence, and the data architecture combine to compress the Innovation Runway, the operational window between a founder’s first FIH decision and the data package their next funding round requires.

    The Bottom Line for Founders

    Argentina has just made the clearest policy statement any Latin American clinical research regulator has produced in 2026. The 62-day pathway under Disposición 7516/25 is operative. The importación simplification is in force. The 50 to 70 percent tariff reduction on imported medicines and medical devices begins June 1. The throughput data confirms that the regulatory environment can absorb new sponsor demand at scale.

    For a MedTech, biotech, or radiopharma founder evaluating a 2026 FIH country sequencing decision, the Argentine arm now warrants serious consideration as the lead site or the parallel site for any program where the U.S. EFS pathway is the comparison baseline. The most expensive FIH decision a founder makes is not the per-patient cost of a single study. It is the calendar cost of choosing the wrong study to run first. Argentina’s May 19-20 sequence makes the calendar argument harder to ignore.

    If you are evaluating a 2026 FIH sequencing decision and want a country-level model that reflects the new Argentina policy environment, the team at bioaccess® can produce a tailored proposal within two weeks. We have run FIH trials across Argentina, Colombia, Brazil, and Mexico since 2010, and our U.S. EFS plus LATAM FIH practice is the only one in Latin America structured to deliver both pathways under a single operational team.

    Citations:

  • Radiopharmaceutical Trials in Latin America: Logistics That Make or Break Your First Patient In

    Radiopharmaceutical Trials in Latin America: Logistics That Make or Break Your First Patient In

    Radiopharmaceutical clinical trials behave differently from most other clinical programs. The “product” is not just a vial—it is a time-sensitive system that includes isotope production, radiolabeling, quality control (QC), packaging, cross-border movement, and last-mile delivery to the imaging suite or treatment room. The most successful programs design these constraints into the protocol from day one.

    Across Latin America, sponsors can unlock faster activation and access to experienced nuclear medicine teams, but they also face logistical realities: variable availability of isotopes, airport cargo limitations, customs clearance variability, and the physics of radioactive decay. A 2026 Pharmaphorum analysis emphasizes that short half-lives require carefully managed distribution, compliance with strict international regulations, specialized packaging, and in some cases decentralized or local radiolabeling rather than centralized manufacturing.

    This article outlines a logistics-first playbook for radiopharmaceutical trials in Latin America, focusing on practical steps that protect schedule, quality, and patient safety without disclosing confidential sponsor details.

    Start with physics: half-life drives everything

    The logistics challenge scales with how quickly your isotope loses usable activity. Pharmaphorum highlights that some isotopes used in radiotherapeutics have very different half-lives, including approximately 6.7 days for Lu-177 and about 10.6 hours for Pb-212. When half-life is short, “time in transit” becomes a clinical performance variable, not merely an operational cost.

    Implication: your trial design must specify not only dose and administration, but also supply chain constraints such as maximum transport duration, acceptable activity range at administration, and contingencies when shipments miss the window.

    Design the supply chain as part of the protocol

    In radiopharma, supply chain and protocol are inseparable. The Pharmaphorum article notes that shipping requires compliance with strict international regulations and specialized packaging. Sponsors should treat packaging qualification, lane qualification, and customs planning as protocol-enabling activities.

    • Define the chain of custody: who releases the batch, who transports it, and who receives it at the site.
    • Define time stamps: end of synthesis, QC release, handoff to carrier, arrival at airport, customs release, receipt at site, administration time.
    • Define acceptance criteria: activity at administration, sterility assurance approach, and temperature/shielding requirements.

    Common pitfall: a protocol that assumes a “normal” drug supply chain will often fail on the first shipment because radiopharma realities (lane availability, airline acceptance, customs timing) were not operationalized.

    Import and transport compliance: plan lead times early

    Cross-border movement of radioactive materials is governed by multiple layers of regulation. Even outside Latin America, the U.S. Department of Transportation’s 49 CFR §173.476 illustrates the compliance mindset regulators expect: offerors must maintain a safety analysis and documentation of tests demonstrating compliance, and certificate requests may need to be received at least 90 days before the requested effective date. The details differ by jurisdiction, but the principle is consistent—radiopharma transport is a regulated process with non-trivial lead times.

    Practical takeaway for LATAM trials: build an “import and transport readiness calendar” that starts months before first patient in. If you wait until sites are activated to address permits and transport documentation, your trial will be delayed even if the science is ready.

    Decentralized radiolabeling: when local production beats centralization

    One of the most important insights from Pharmaphorum is that short-half-life isotopes can force local radiolabeling. The article explains that while longer half-life isotopes can be labeled in centralized facilities, Pb-212’s shorter half-life necessitates local radiolabeling and therefore a wider geographic footprint. This is a strategic decision: do you build a hub-and-spoke network, partner with regional capabilities, or choose an isotope/asset combination that is more forgiving for your operational footprint?

    • Hub-and-spoke model: install generator or labeling capability in a regional hub and distribute doses to nearby sites.
    • Site-embedded model: enable radiolabeling at select high-capability hospitals.
    • Hybrid model: start with one hub for early-phase feasibility, then expand regionally as you scale enrollment.

    Key decision criterion: the relationship between half-life, flight schedules, customs predictability, and on-site capacity to release product to patients.

    Operational playbook: a 10-point readiness checklist

    • 1) Lane qualification: choose airports and carriers that routinely accept radioactive cargo and can document handling.
    • 2) Packaging validation: confirm shielding, labeling, and any required temperature control under realistic transit times.
    • 3) QC release plan: clarify which tests are performed before shipment vs. at/near site, and how results are documented.
    • 4) Customs “fast track” alignment: prepare documentation so the shipment’s purpose and classification are unambiguous.
    • 5) Missed-window contingency: define what happens if activity is below threshold at arrival.
    • 6) Scheduling discipline: align patient visits, imaging slots, and dosing windows to inbound shipment timing.
    • 7) Training: ensure site staff understand receipt, storage, radiation safety basics, and administration workflows.
    • 8) Data capture: capture time stamps and activity measurements as structured data for operational learning.
    • 9) Vendor oversight: manage carriers and depots like critical clinical vendors, not like routine couriers.
    • 10) Scale strategy: expand to new countries only after proving repeatable shipment-to-administration performance.

    FAQ

    1) What is the biggest logistics risk in radiopharmaceutical clinical trials?

    For many programs, the biggest risk is the mismatch between isotope half-life and real-world transit time. If the product loses activity before administration, schedule and enrollment are immediately impacted.

    2) When is local radiolabeling necessary?

    Pharmaphorum notes that for very short half-life isotopes such as Pb-212 (about 10.6 hours), local radiolabeling may be necessary because centralized labeling can be incompatible with transit time and decay.

    3) How should sponsors plan for regulatory transport requirements?

    Start early and assume non-trivial lead times. Regulations like 49 CFR §173.476 show that authorities expect documented safety analyses and, in some cases, certificate requests planned months in advance. Use that mindset to build a transport-ready process tailored to each participating LATAM jurisdiction.

    Educational content only. Sponsors should consult qualified radiopharmaceutical manufacturing, logistics, and regulatory experts for trial-specific requirements.

  • Navigate Ethics Committee Approval For Clinical Trials In Brazil

    <h2 id="introduction">Introduction</h2>

    <p>Understanding the pivotal role of ethics committees is essential for successfully navigating clinical trials in Brazil. This guide outlines the essential steps for obtaining ethics committee approval and highlights recent legislative changes that enhance trial initiation efficiency.</p>

    <p>However, researchers often face significant challenges, including:</p>

    <ul>

    <li>Lengthy approval timelines</li>

    <li>Complex documentation requirements</li>

    </ul>

    <p>What strategies can sponsors employ to overcome these hurdles and ensure their clinical studies launch on time? These challenges can lead to delays that jeopardize the entire research timeline. Addressing these challenges head-on is crucial for ensuring timely and successful clinical study launches.</p>

    <h2 id="understand-the-role-of-ethics-committees-in-clinical-trials">Understand the Role of Ethics Committees in Clinical Trials</h2>

    <p>Navigating the complexities of clinical research in Brazil hinges on understanding the pivotal role of <a href="https://bioaccessla.com/news/axoft-receives-ethics-committee-approval-for-first-in-human-clinical-trial-in-panama">ethics committee approval</a> for conducting a <a href="https://bioaccessla.com/br/contact-us">clinical trial</a>, which is essential for safeguarding participant welfare and ensuring compliance with ethical standards. Let’s explore their key functions:</p>

    <ol>

    <li>Protocol Review: Ethics committees meticulously evaluate research protocols to confirm that study designs are ethical and that risks to participants are minimized. This assessment is essential for ensuring participant safety and confirming that the study is scientifically sound.</li>

    <li>Informed Consent: They assess <a href="https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety" rel="noopener noreferrer nofollow" target="_blank">informed consent documents</a> to guarantee that participants are fully informed about the study, including potential risks and benefits. This process is vital for upholding the autonomy and rights of participants.</li>

    <li>Continuous Oversight: Throughout the study, review boards provide ongoing supervision to ensure adherence to standards and to address any adverse events that may occur. This ongoing monitoring is essential for maintaining the integrity of the research.</li>

    <li><a href="https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety" rel="noopener noreferrer nofollow" target="_blank">Authorization Process</a>: Before a clinical study can begin, it must obtain ethics committee approval for the Brazil clinical trial, which is a prerequisite for submission to ANVISA (Agência Nacional de Vigilância Sanitária). The ethical review must be finalized within 30 business days from the acceptance of all research documents, significantly affecting the overall timeline for study initiation. If additional information is required, delays in the authorization process can hinder timely study initiation, impacting research outcomes.</li>

    </ol>

    <p>Comprehending these roles is essential for navigating the authorization process efficiently, especially for <a href="https://bioaccessla.com/br/services">first-in-human studies</a> where ethical concerns are critical. With the <a href="https://psi-cro.com/brazil-new-clinical-research-law" rel="noopener noreferrer nofollow" target="_blank">new law</a>, researchers can expect a more streamlined authorization process, allowing for quicker study launches. As the landscape evolves with new regulations, staying informed about these changes will be crucial for researchers aiming to expedite their studies while upholding ethical integrity.</p>

    <p><img alt="This mindmap illustrates the essential roles of ethics committees in clinical trials. Start at the center with the main role, then follow the branches to see each specific function and its importance in ensuring ethical standards and participant safety." src="https://images.tely.ai/telyai/eyvmppxa-this-mindmap-illustrates-the-essential-roles-of-ethics-committees-in-clinical-trials-start-at-the-center-with-the-main-role-then-follow-the-branches-to-see-each-specific-function-and-its-importance-in-ensuring-ethical-standards-and-participant-safety.webp" title="This mindmap illustrates the essential roles of ethics committees in clinical trials. Start at the center with the main role, then follow the branches to see each specific function and its importance in ensuring ethical standards and participant safety."/></p>

    <h2 id="review-brazils-regulatory-framework-for-ethics-approval">Review Brazil's Regulatory Framework for Ethics Approval</h2>

    <p>Navigating Brazil's evolving regulatory landscape for clinical research sponsors involves obtaining <a href="https://bioaccessla.com/es/services">ethics committee approval for clinical trials</a>, presenting both challenges and opportunities. The regulatory framework for studies is primarily overseen by ANVISA and the <a href="https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil" rel="noopener noreferrer nofollow" target="_blank">newly formed National Ethics Committee (INAEP)</a>, which is essential for obtaining ethics committee approval for <a href="https://bioaccessla.com/latin-america-medtech-research-site-search-and-selection">Brazil clinical trials</a>. Here are the key components of this framework:</p>

    <ol>

    <li>ANVISA Submission: All <a href="https://bioaccessla.com/services">clinical trials must be submitted to ANVISA</a> for evaluation. The review process is limited to 90 business days, greatly improving the pace of authorizations compared to prior timelines.</li>

    <li>Under INAEP Oversight, researchers must now secure <a href="https://bioaccessla.com/blog/5-key-practices-for-patient-safety-under-cofepris-regulations">ethics committee approval in Brazil</a> for the clinical trial before submitting to ANVISA. This ensures that <a href="https://bioaccessla.com/blog/4-best-practices-for-fda-guidance-validation-in-clinical-research">ethical standards are upheld</a> throughout the research process, including the requirement for ethics committee approval for the Brazil clinical trial, with INAEP supervising local committees to maintain consistency.</li>

    <li><a href="https://bioaccessla.com/blog/10-serbian-sop-templates-for-streamlined-trial-compliance">Plataforma Brasil</a>: Researchers must register their studies on Plataforma Brasil, the national system for ethical clearance. This platform simplifies the submission process and enables tracking of endorsements, enhancing communication among stakeholders.</li>

    <li>New Regulations: As of May 2024, Brazil enacted <a href="https://clinicalleader.com/doc/how-brazil-s-new-law-is-redefining-the-country-s-clinical-research-0001" rel="noopener noreferrer nofollow" target="_blank">Law No. 14.874</a>, which streamlines the process by permitting simultaneous submissions to ANVISA and review boards. This regulatory flexibility is anticipated to encourage innovation and enhance Brazil's competitiveness in the global research landscape.</li>

    </ol>

    <p>Understanding this regulatory framework is crucial for sponsors who want to effectively navigate the complexities of ethical consent and obtain ethics committee approval for a clinical trial in Brazil. These changes position Brazil as a more attractive destination for innovative clinical research, fostering growth in the Medtech sector.</p>

    <p><img alt="This flowchart outlines the steps needed to obtain ethics committee approval for clinical trials in Brazil. Each box represents a key step in the process, and the arrows show the order in which these steps should be completed. Follow the flow to understand how to navigate the regulatory landscape effectively." src="https://images.tely.ai/telyai/dwholqnu-this-flowchart-outlines-the-steps-needed-to-obtain-ethics-committee-approval-for-clinical-trials-in-brazil-each-box-represents-a-key-step-in-the-process-and-the-arrows-show-the-order-in-which-these-steps-should-be-completed-follow-the-flow-to-understand-how-to-navigate-the-regulatory-landscape-effectively.webp" title="This flowchart outlines the steps needed to obtain ethics committee approval for clinical trials in Brazil. Each box represents a key step in the process, and the arrows show the order in which these steps should be completed. Follow the flow to understand how to navigate the regulatory landscape effectively."/></p>

    <h2 id="prepare-and-submit-required-documentation-for-approval">Prepare and Submit Required Documentation for Approval</h2>

    <p>Gaining <a href="https://bioaccessla.com/market-access">ethics committee approval</a> for a clinical trial in Brazil is a critical yet intricate process that demands meticulous attention to detail. To navigate this landscape effectively, sponsors must prepare and submit a comprehensive set of documents. Here’s a step-by-step guide:</p>

    <ol>

    <li>

    <p>Compile <a href="https://bioaccessla.com/blog/10-essential-edc-software-features-for-clinical-research-directors">Essential Documents</a>: The following documents are typically required:</p>

    <ul>

    <li>Research protocol</li>

    <li>Informed consent forms</li>

    <li>Investigator's brochure</li>

    <li>Case report forms (CRFs)</li>

    <li>Ethics committee approval from the local CEP</li>

    <li>Any previous approvals or correspondence with <a href="https://bioaccessla.com/resources">regulatory bodies</a></li>

    </ul>

    </li>

    <li>

    <p>Register on <a href="https://bioaccessla.com/blog/10-key-regulatory-considerations-for-rare-disease-trials-in-romania">Plataforma Brasil</a>: Create an account on Plataforma Brasil, the national registry for clinical research, and register your study. Ensure that all required documents are uploaded in the correct format, including electronic copies with text searching capability.</p>

    </li>

    <li>

    <p>Submit to Local CEP: Once registered, submit your application to the <a href="https://bioaccessla.com/blog/10-steps-for-effective-ec-ce-compliance-in-medical-devices">local committee</a> for review. This submission must include all necessary documentation and a cover letter outlining the study's objectives and significance. The CEP will review the protocol documentation for completeness within 10 days of submission and issue an initial report within 30 days after full acceptance of the protocol documents.</p>

    </li>

    <li>

    <p>Follow Up: After submission, staying in touch with the review board can really help make the review process smoother. Address any questions or requests for additional information promptly to facilitate a more efficient review.</p>

    </li>

    <li>

    <p>Prepare for <a href="https://globalregulatorypartners.com/clinical-trials-for-drugs-medicines-in-brazil-and-the-clinical-trial-application-process" rel="noopener noreferrer nofollow" target="_blank">ANVISA Submission</a>: Once you obtain consent from the local CEP, prepare your submission for ANVISA. You need to ensure that all documents meet their criteria. This includes proof of the ethics committee approval for the Brazil clinical trial and a detailed research protocol. ANVISA generally requires 90 calendar days to assess the application, and if no feedback is provided within this period, development can proceed, assuming ethical permissions are in place.</p>

    </li>

    </ol>

    <p>Ultimately, a well-prepared submission can significantly streamline the path to successful <a href="https://bioaccessla.com/br/about">clinical trials in Brazil</a>.</p>

    <p><img alt="This flowchart shows the steps you need to take to get approval for a clinical trial in Brazil. Start at the top and follow the arrows down to see what you need to do at each stage, including what documents to prepare and where to submit them." src="https://images.tely.ai/telyai/lmoybooh-this-flowchart-shows-the-steps-you-need-to-take-to-get-approval-for-a-clinical-trial-in-brazil-start-at-the-top-and-follow-the-arrows-down-to-see-what-you-need-to-do-at-each-stage-including-what-documents-to-prepare-and-where-to-submit-them.webp" title="This flowchart shows the steps you need to take to get approval for a clinical trial in Brazil. Start at the top and follow the arrows down to see what you need to do at each stage, including what documents to prepare and where to submit them."/></p>

    <h2 id="identify-and-overcome-common-challenges-in-the-approval-process">Identify and Overcome Common Challenges in the Approval Process</h2>

    <p>Navigating the review process for research in Brazil can present several challenges that may impede <a href="https://bioaccessla.com/br/news">timely progress</a>. Here are some common obstacles and strategies to overcome them:</p>

    <ol>

    <li><a href="https://bioaccessla.com/blog/10-essential-steps-of-randomised-control-trial-for-clinical-success">Lengthy Approval Times</a>: Authorization from review boards can take longer than anticipated, often surpassing 180 days under the previous system. Recent <a href="https://bioaccessla.com/solutions">regulatory changes</a> now allow for a maximum approval time of just 30 days for standard submissions, and even less for strategic research. To mitigate delays, submit your application well in advance and ensure that all documentation is complete and accurate.</li>

    <li><a href="https://bioaccessla.com/blog/10-croatia-ethics-committee-so-ps-every-sponsor-must-know">Incomplete Documentation</a>: One of the most common reasons for delays is incomplete submissions. Statistics show that incomplete documentation is a significant factor in delays of authorization. Make sure to use a comprehensive checklist to confirm that all required documents, including Informed Consent Forms (ICFs) and study protocols, are included before submission.</li>

    <li><a href="https://bioaccessla.com/blog/7-strategies-to-enhance-diversity-in-clinical-trials">Communication Gaps</a>: Maintain open lines of communication with the compliance committee. Regularly follow up on the status of your application and be responsive to any requests for additional information. This proactive approach can help clarify any uncertainties and expedite the review process.</li>

    <li>Regulatory Changes: Stay informed about changes in regulations, such as the recent enactment of <a href="https://ibanet.org/Brazil-enacts-new-law-to-regulate-clinical-trials" rel="noopener noreferrer nofollow" target="_blank">Law No. 14,874/2024 and Executive Order #12,651/2025</a>, which simplify the process for obtaining consent. Subscribe to updates from ANVISA and the National Research Ethics Board (INEP) to remain compliant and aware of any new requirements.</li>

    <li>Cultural Differences: Grasping the local context and cultural subtleties can enable smoother interactions with review committees. Engaging local experts or consultants who are familiar with the Brazilian regulatory landscape can provide valuable insights and enhance communication.</li>

    </ol>

    <p>Addressing these challenges not only streamlines the approval process but also positions sponsors for success in bringing innovative therapies to market.</p>

    <p><img alt="Each box represents a challenge faced during the approval process, and the arrows lead to strategies that can help overcome these challenges. Follow the flow to see how to tackle each obstacle effectively." src="https://images.tely.ai/telyai/ijcsaudr-each-box-represents-a-challenge-faced-during-the-approval-process-and-the-arrows-lead-to-strategies-that-can-help-overcome-these-challenges-follow-the-flow-to-see-how-to-tackle-each-obstacle-effectively.webp" title="Each box represents a challenge faced during the approval process, and the arrows lead to strategies that can help overcome these challenges. Follow the flow to see how to tackle each obstacle effectively."/></p>

    <h2 id="conclusion">Conclusion</h2>

    <p>The ethics committee approval process in Brazil presents both challenges and opportunities for clinical trial researchers. Researchers must grasp the vital roles of ethics committees, which range from reviewing protocols to providing ongoing oversight. The recent regulatory changes have streamlined this process, offering a clearer path for obtaining necessary approvals.</p>

    <p>This article highlights key components of Brazil's regulatory framework, including the importance of ANVISA submissions and the need for registering on Plataforma Brasil. Navigating the registration process on Plataforma Brasil can be daunting for many researchers. Additionally, the new law facilitates simultaneous submissions, simplifying the process and accelerating the timeline for research initiatives. Comprehensive documentation and proactive communication with ethics committees are essential to overcoming common challenges, such as lengthy approval times and incomplete submissions.</p>

    <p>Ultimately, the significance of ethics committee approval extends beyond compliance; it fosters a culture of safety and respect for participants in clinical trials. By understanding and addressing the challenges outlined, researchers can enhance their chances of success in bringing innovative therapies to market. Engaging with local experts and staying informed about regulatory changes will not only expedite the approval process but also position Brazil as a competitive player in the global clinical research landscape. By mastering these processes, researchers can not only ensure compliance but also contribute to the advancement of medical science in Brazil.</p>

    <p><iframe frameborder="0" height="300px" loading="lazy" src="https://iframe.tely.ai/cta/eyJhcnRpY2xlX2lkIjogIjY5ZjUzZWY4ODdhNmQ3Y2IxOTU5MjYyZCIsICJjb21wYW55X2lkIjogIjY2OTk4NmYwMzM1YWQwNDI3ZTVmNTdlMyIsICJpbmRleCI6IG51bGwsICJ0eXBlIjogImFydGljbGUifQ==" width="100%"></iframe></p>

    <h2 id="frequently-asked-questions">Frequently Asked Questions</h2>

    <p><strong>What is the role of ethics committees in clinical trials in Brazil?</strong></p>

    <p>Ethics committees play a crucial role in clinical trials in Brazil by reviewing research protocols to ensure they are ethical, assessing informed consent documents to protect participant rights, providing continuous oversight during the study, and approving studies before they can begin.</p>

    <p><strong>How do ethics committees evaluate research protocols?</strong></p>

    <p>Ethics committees meticulously evaluate research protocols to confirm that study designs are ethical and that risks to participants are minimized, ensuring participant safety and scientific soundness.</p>

    <p><strong>What is the importance of informed consent in clinical trials?</strong></p>

    <p>Informed consent is vital as ethics committees assess the consent documents to ensure participants are fully informed about the study, including potential risks and benefits, thereby upholding their autonomy and rights.</p>

    <p><strong>What kind of oversight do ethics committees provide during a clinical study?</strong></p>

    <p>Ethics committees provide ongoing supervision throughout the study to ensure adherence to ethical standards and to address any adverse events that may occur, maintaining the integrity of the research.</p>

    <p><strong>What is the authorization process for a clinical study in Brazil?</strong></p>

    <p>Before a clinical study can commence, it must obtain ethics committee approval, which is a prerequisite for submission to ANVISA. The ethical review must be finalized within 30 business days from the acceptance of all research documents.</p>

    <p><strong>How can delays in the authorization process impact clinical trials?</strong></p>

    <p>If additional information is required during the ethics committee review, it can delay the authorization process, hindering timely study initiation and potentially impacting research outcomes.</p>

    <p><strong>What recent changes have been made to the authorization process for clinical trials?</strong></p>

    <p>Recent changes in the law have led to a more streamlined authorization process, allowing for quicker study launches, which is particularly beneficial for first-in-human studies where ethical concerns are critical.</p>

    <p><strong>Why is it important for researchers to stay informed about changes in regulations?</strong></p>

    <p>Staying informed about evolving regulations is crucial for researchers aiming to expedite their studies while maintaining ethical integrity, especially in the context of first-in-human and early feasibility clinical trials.</p>

    <h2 id="list-of-sources">List of Sources</h2>

    <ol>

    <li>Understand the Role of Ethics Committees in Clinical Trials

    <ul>

    <li>What to Know About Brazil’s New Clinical Research Law (https://psi-cro.com/brazil-new-clinical-research-law)</li>

    <li>Avaliação de ensaios clínicos no Brasil: histórico e atualidades (https://scielo.br/j/bioet/a/Bhk4bDL8wYTZtPc6PrpWycQ?format=pdf&amp;lang=en)</li>

    <li>The Role of Ethics Committees in Clinical Trials – TFS HealthScience | Contract Research Organization | Global Resourcing Provider | CRO (https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety)</li>

    <li>7 essential roles of ethics committee in clinical trials (https://pharmaeducenter.com/blog/role-of-ethics-committee-in-clinical-trials)</li>

    </ul>

    </li>

    <li>Review Brazil's Regulatory Framework for Ethics Approval

    <ul>

    <li>Brazil Just Changed The Rules For Clinical Trial Approvals — What Sponsors Need To Know | bioaccess® (https://bioaccessla.com/blog/brazil-anvisa-parallel-review-clinical-trial-approvals-2026)</li>

    <li>New regulations for clinical research in Brazil | Licks Attorneys (https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil)</li>

    <li>Brazil Cuts Clinical Trial Approval Timeline to 90 Days | bioaccess®: Fast-Tracking First-in-Human Trials, Anywhere posted on the topic | LinkedIn (https://linkedin.com/posts/bioaccess_clinicaltrials-brazil-anvisa-activity-7447976698958106627-98MW)</li>

    <li>How Brazil's New Law Is Redefining The Country's Clinical Research (https://clinicalleader.com/doc/how-brazil-s-new-law-is-redefining-the-country-s-clinical-research-0001)</li>

    </ul>

    </li>

    <li>Prepare and Submit Required Documentation for Approval

    <ul>

    <li>Clinical Trial Regulatory Process – Brazil | Credevo Articles (https://credevo.com/articles/2019/03/14/clinical-trial-regulatory-process-brazil)</li>

    <li>Clinical Trials for Drugs/Medicines in Brazil and the Clinical Trial Application process (https://globalregulatorypartners.com/clinical-trials-for-drugs-medicines-in-brazil-and-the-clinical-trial-application-process)</li>

    </ul>

    </li>

    <li>Identify and Overcome Common Challenges in the Approval Process

    <ul>

    <li>New regulations for clinical research in Brazil | Licks Attorneys (https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil)</li>

    <li>Brazil enacts a law to regulate clinical trials (https://ibanet.org/Brazil-enacts-new-law-to-regulate-clinical-trials)</li>

    <li>Best Practices For First-In-Human Clinical Trials In Brazil | bioaccess® (https://bioaccessla.com/blog/best-practices-for-first-in-human-clinical-trials-in-brazil)</li>

    <li>Understanding Ethics Committee Considerations … | bioaccess® (https://bioaccessla.com/blog/understanding-ethics-committee-considerations-in-brazil-a-comprehensive-tutorial)</li>

    </ul>

    </li>

    </ol>

    <script type="application/ld+json">{"@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [{"@type": "Question", "name": "What is the role of ethics committees in clinical trials in Brazil?", "acceptedAnswer": {"@type": "Answer", "text": "Ethics committees play a crucial role in clinical trials in Brazil by reviewing research protocols to ensure they are ethical, assessing informed consent documents to protect participant rights, providing continuous oversight during the study, and approving studies before they can begin."}}, {"@type": "Question", "name": "How do ethics committees evaluate research protocols?", "acceptedAnswer": {"@type": "Answer", "text": "Ethics committees meticulously evaluate research protocols to confirm that study designs are ethical and that risks to participants are minimized, ensuring participant safety and scientific soundness."}}, {"@type": "Question", "name": "What is the importance of informed consent in clinical trials?", "acceptedAnswer": {"@type": "Answer", "text": "Informed consent is vital as ethics committees assess the consent documents to ensure participants are fully informed about the study, including potential risks and benefits, thereby upholding their autonomy and rights."}}, {"@type": "Question", "name": "What kind of oversight do ethics committees provide during a clinical study?", "acceptedAnswer": {"@type": "Answer", "text": "Ethics committees provide ongoing supervision throughout the study to ensure adherence to ethical standards and to address any adverse events that may occur, maintaining the integrity of the research."}}, {"@type": "Question", "name": "What is the authorization process for a clinical study in Brazil?", "acceptedAnswer": {"@type": "Answer", "text": "Before a clinical study can commence, it must obtain ethics committee approval, which is a prerequisite for submission to ANVISA. The ethical review must be finalized within 30 business days from the acceptance of all research documents."}}, {"@type": "Question", "name": "How can delays in the authorization process impact clinical trials?", "acceptedAnswer": {"@type": "Answer", "text": "If additional information is required during the ethics committee review, it can delay the authorization process, hindering timely study initiation and potentially impacting research outcomes."}}, {"@type": "Question", "name": "What recent changes have been made to the authorization process for clinical trials?", "acceptedAnswer": {"@type": "Answer", "text": "Recent changes in the law have led to a more streamlined authorization process, allowing for quicker study launches, which is particularly beneficial for first-in-human studies where ethical concerns are critical."}}, {"@type": "Question", "name": "Why is it important for researchers to stay informed about changes in regulations?", "acceptedAnswer": {"@type": "Answer", "text": "Staying informed about evolving regulations is crucial for researchers aiming to expedite their studies while maintaining ethical integrity, especially in the context of first-in-human and early feasibility clinical trials."}}]}</script><script type="application/ld+json">{"@context": "https://schema.org", "@type": "BlogPosting", "headline": "Navigate Ethics Committee Approval for Clinical Trials in Brazil", "description": "Navigate the ethics committee approval process for clinical trials in Brazil efficiently and successfully.", "datePublished": "2026-05-02T00:02:00.602000", "dateModified": "2026-05-02T04:47:39.578139+00:00", "articleBody": "## IntroductionnUnderstanding the pivotal role of ethics committees is essential for successfully navigating clinical trials in Brazil. This guide outlines the essential steps for obtaining ethics committee approval and highlights recent legislative changes that enhance trial initiation efficiency. nnHowever, researchers often face significant challenges, including:nn- Lengthy approval timelinesn- Complex documentation requirementsnnWhat strategies can sponsors employ to overcome these hurdles and ensure their clinical studies launch on time? These challenges can lead to delays that jeopardize the entire research timeline. Addressing these challenges head-on is crucial for ensuring timely and successful clinical study launches.nn## Understand the Role of Ethics Committees in Clinical TrialsnnNavigating the complexities of clinical research in Brazil hinges on understanding the pivotal role of [ethics committee approval](https://bioaccessla.com/news/axoft-receives-ethics-committee-approval-for-first-in-human-clinical-trial-in-panama) for conducting a [clinical trial](https://bioaccessla.com/br/contact-us), which is essential for safeguarding participant welfare and ensuring compliance with ethical standards. Let’s explore their key functions:nn1. Protocol Review: Ethics committees meticulously evaluate research protocols to confirm that study designs are ethical and that risks to participants are minimized. This assessment is essential for ensuring participant safety and confirming that the study is scientifically sound.n2. Informed Consent: They assess [informed consent documents](https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety) to guarantee that participants are fully informed about the study, including potential risks and benefits. This process is vital for upholding the autonomy and rights of participants.n3. Continuous Oversight: Throughout the study, review boards provide ongoing supervision to ensure adherence to standards and to address any adverse events that may occur. This ongoing monitoring is essential for maintaining the integrity of the research.n4. [Authorization Process](https://tfscro.com/resources/the-role-of-ethics-committees-in-clinical-trials-ensuring-patient-safety): Before a clinical study can begin, it must obtain ethics committee approval for the Brazil clinical trial, which is a prerequisite for submission to ANVISA (Agência Nacional de Vigilância Sanitária). The ethical review must be finalized within 30 business days from the acceptance of all research documents, significantly affecting the overall timeline for study initiation. If additional information is required, delays in the authorization process can hinder timely study initiation, impacting research outcomes.nnComprehending these roles is essential for navigating the authorization process efficiently, especially for [first-in-human studies](https://bioaccessla.com/br/services) where ethical concerns are critical. With the [new law](https://psi-cro.com/brazil-new-clinical-research-law), researchers can expect a more streamlined authorization process, allowing for quicker study launches. As the landscape evolves with new regulations, staying informed about these changes will be crucial for researchers aiming to expedite their studies while upholding ethical integrity.nn![This mindmap illustrates the essential roles of ethics committees in clinical trials. Start at the center with the main role, then follow the branches to see each specific function and its importance in ensuring ethical standards and participant safety.](https://images.tely.ai/telyai/eyvmppxa-this-mindmap-illustrates-the-essential-roles-of-ethics-committees-in-clinical-trials-start-at-the-center-with-the-main-role-then-follow-the-branches-to-see-each-specific-function-and-its-importance-in-ensuring-ethical-standards-and-participant-safety.webp "This mindmap illustrates the essential roles of ethics committees in clinical trials. Start at the center with the main role, then follow the branches to see each specific function and its importance in ensuring ethical standards and participant safety.")nn## Review Brazil's Regulatory Framework for Ethics ApprovalnnNavigating Brazil's evolving regulatory landscape for clinical research sponsors involves obtaining [ethics committee approval for clinical trials](https://bioaccessla.com/es/services), presenting both challenges and opportunities. The regulatory framework for studies is primarily overseen by ANVISA and the [newly formed National Ethics Committee (INAEP)](https://lickslegal.com/post/new-regulations-for-clinical-research-in-brazil), which is essential for obtaining ethics committee approval for [Brazil clinical trials](https://bioaccessla.com/latin-america-medtech-research-site-search-and-selection). Here are the key components of this framework:nn1. ANVISA Submission: All [clinical trials must be submitted to ANVISA](https://bioaccessla.com/services) for evaluation. The review process is limited to 90 business days, greatly improving the pace of authorizations compared to prior timelines.n2. Under INAEP Oversight, researchers must now secure [ethics committee approval in Brazil](https://bioaccessla.com/blog/5-key-practices-for-patient-safety-under-cofepris-regulations) for the clinical trial before submitting to ANVISA. This ensures that [ethical standards are upheld](https://bioaccessla.com/blog/4-best-practices-for-fda-guidance-validation-in-clinical-research) throughout the research process, including the requirement for ethics committee approval for the Brazil clinical trial, with INAEP supervising local committees to maintain consistency.n3. [Plataforma Brasil](https://bioaccessla.com/blog/10-serbian-sop-templates-for-streamlined-trial-compliance): Researchers must register their studies on Plataforma Brasil, the national system for ethical clearance. This platform simplifies the submission process and enables tracking of endorsements, enhancing communication among stakeholders.n4. New Regulations: As of May 2024, Brazil enacted [Law No. 14.874](https://clinicalleader.com/doc/how-brazil-s-new-law-is-redefining-the-country-s-clinical-research-0001), which streamlines the process by permitting simultaneous submissions to ANVISA and review boards. This regulatory flexibility is anticipated to encourage innovation and enhance Brazil's competitiveness in the global research landscape.nnUnderstanding this regulatory framework is crucial for sponsors who want to effectively navigate the complexities of ethical consent and obtain ethics committee approval for a clinical trial in Brazil. These changes position Brazil as a more attractive destination for innovative clinical research, fostering growth in the Medtech sector.nn![This flowchart outlines the steps needed to obtain ethics committee approval for clinical trials in Brazil. Each box represents a key step in the process, and the arrows show the order in which these steps should be completed. Follow the flow to understand how to navigate the regulatory landscape effectively.](https://images.tely.ai/telyai/dwholqnu-this-flowchart-outlines-the-steps-needed-to-obtain-ethics-committee-approval-for-clinical-trials-in-brazil-each-box-represents-a-key-step-in-the-process-and-the-arrows-show-the-order-in-which-these-steps-should-be-completed-follow-the-flow-to-understand-how-to-navigate-the-regulatory-landscape-effectively.webp "This flowchart outlines the steps needed to obtain ethics committee approval for clinical trials in Brazil. Each box represents a key step in the process, and the arrows show the order in which these steps should be completed. Follow the flow to understand how to navigate the regulatory landscape effectively.")nn## Prepare and Submit Required Documentation for ApprovalnnGaining [ethics committee approval](https://bioaccessla.com/market-access) for a clinical trial in Brazil is a critical yet intricate process that demands meticulous attention to detail. To navigate this landscape effectively, sponsors must prepare and submit a comprehensive set of documents. Here’s a step-by-step guide:nn1. Compile [Essential Documents](https://bioaccessla.com/blog/10-essential-edc-software-features-for-clinical-research-directors): The following documents are typically required:nn   – Research protocoln   – Informed consent formsn   – Investigator's brochuren   – Case report forms (CRFs)n   – Ethics committee approval from the local CEPn   – Any previous approvals or correspondence with [regulatory bodies](https://bioaccessla.com/resources)n2. Register on [Plataforma Brasil](https://bioaccessla.com/blog/10-key-regulatory-considerations-for-rare-disease-trials-in-romania): Create an account on Plataforma Brasil, the national registry for clinical research, and register your study. Ensure that all required documents are uploaded in the correct format, including electronic copies with text searching capability.n3. Submit to Local CEP: Once registered, submit your application to the [local committee](https://bioaccessla.com/blog/10-steps-for-effective-ec-ce-compliance-in-medical-devices) for review. This submission must include all necessary documentation and a cover letter outlining the study's objectives and significance. The CEP will review the protocol documentation for completeness within 10 days of submission and issue an initial report within 30 days after full acceptance of the protocol documents.n4. Follow Up: After submission, staying in touch with the review board can really help make the review process smoother. Address any questions or requests for additional information promptly to facilitate a more efficient review.n5. Prepare for [ANVISA Submission](https://globalregulatorypartners.com/clinical-trials-for-drugs-medicines-in-brazil-and-the-clinical-trial-application-process): Once you obtain consent from the local CEP, prepare your submission for ANVISA. You need to ensure that all documents meet their criteria. This includes proof of the ethics committee approval for the Brazil clinical trial and a detailed research protocol. ANVISA generally requires 90 calendar days to assess the application, and if no feedback is provided within this period, development can proceed, assuming ethical permissions are in place.nnUltimately, a well-prepared submission can significantly streamline the path to successful [clinical trials in Brazil](https://bioaccessla.com/br/about).nn![This flowchart shows the steps you need to take to get approval for a clinical trial in Brazil. Start at the top and follow the arrows down to see what you need to do at each stage, including what documents to prepare and where to submit them.](https://images.tely.ai/telyai/lmoybooh-this-flowchart-shows-the-steps-you-need-to-take-to-get-approval-for-a-clinical-trial-in-brazil-start-at-the-top-and-follow-the-arrows-down-to-see-what-you-need-to-do-at-each-stage-including-what-documents-to-prepare-and-where-to-submit-them.webp "This flowchart shows the steps you need to take to get approval for a clinical trial in Brazil. Start at the top and follow the arrows down to see what you need to do at each stage, including what documents to prepare and where to submit them.")nn## Identify and Overcome Common Challenges in the Approval ProcessnnNavigating the review process for research in Brazil can present several challenges that may impede [timely progress](https://bioaccessla.com/br/news). Here are some common obstacles and strategies to overcome them:nn1. [Lengthy Approval Times](https://bioaccessla.com/blog/10-essential-steps-of-randomised-control-trial-for-clinical-success): Authorization from review boards can take longer than anticipated, often surpassing 180 days under the previous system. Recent [regulatory changes](https://bioaccessla.com/solutions) now allow for a maximum approval time of just 30 days for standard submissions, and even less for strategic research. To mitigate delays, submit your application well in advance and ensure that all documentation is complete and accurate.n2. [Incomplete Documentation](https://bioaccessla.com/blog/10-croatia-ethics-committee-so-ps-every-sponsor-must-know): One of the most common reasons for delays is incomplete submissions. Statistics show that incomplete documentation is a significant factor in delays of authorization. Make sure to use a comprehensive checklist to confirm that all required documents, including Informed Consent Forms (ICFs) and study protocols, are included before submission.n3. [Communication Gaps](https://bioaccessla.com/blog/7-strategies-to-enhance-diversity-in-clinical-trials): Maintain open lines of communication with the compliance committee. Regularly follow up on the status of your application and be responsive to any requests for additional information. This proactive approach can help clarify any uncertainties and expedite the review process.n4. Regulatory Changes: Stay informed about changes in regulations, such as the recent enactment of [Law No. 14,874/2024 and Executive Order #12,651/2025](https://ibanet.org/Brazil-enacts-new-law-to-regulate-clinical-trials), which simplify the process for obtaining consent. Subscribe to updates from ANVISA and the National Research Ethics Board (INEP) to remain compliant and aware of any new requirements.n5. Cultural Differences: Grasping the local context and cultural subtleties can enable smoother interactions with review committees. Engaging local experts or consultants who are familiar with the Brazilian regulatory landscape can provide valuable insights and enhance communication.nnAddressing these challenges not only streamlines the approval process but also positions sponsors for success in bringing innovative therapies to market.nn![Each box represents a challenge faced during the approval process, and the arrows lead to strategies that can help overcome these challenges. Follow the flow to see how to tackle each obstacle effectively.](https://images.tely.ai/telyai/ijcsaudr-each-box-represents-a-challenge-faced-during-the-approval-process-and-the-arrows-lead-to-strategies-that-can-help-overcome-these-challenges-follow-the-flow-to-see-how-to-tackle-each-obstacle-effectively.webp "Each box represents a challenge faced during the approval process, and the arrows lead to strategies that can help overcome these challenges. Follow the flow to see how to tackle each obstacle effectively.")nn## ConclusionnThe ethics committee approval process in Brazil presents both challenges and opportunities for clinical trial researchers. Researchers must grasp the vital roles of ethics committees, which range from reviewing protocols to providing ongoing oversight. The recent regulatory changes have streamlined this process, offering a clearer path for obtaining necessary approvals.  nnThis article highlights key components of Brazil's regulatory framework, including the importance of ANVISA submissions and the need for registering on Plataforma Brasil. Navigating the registration process on Plataforma Brasil can be daunting for many researchers. Additionally, the new law facilitates simultaneous submissions, simplifying the process and accelerating the timeline for research initiatives. Comprehensive documentation and proactive communication with ethics committees are essential to overcoming common challenges, such as lengthy approval times and incomplete submissions.  nnUltimately, the significance of ethics committee approval extends beyond compliance; it fosters a culture of safety and respect for participants in clinical trials. By understanding and addressing the challenges outlined, researchers can enhance their chances of success in bringing innovative therapies to market. Engaging with local experts and staying informed about regulatory changes will not only expedite the approval process but also position Brazil as a competitive player in the global clinical research landscape. By mastering these processes, researchers can not only ensure compliance but also contribute to the advancement of medical science in Brazil.nn::iframe[https://iframe.tely.ai/cta/eyJhcnRpY2xlX2lkIjogIjY5ZjUzZWY4ODdhNmQ3Y2IxOTU5MjYyZCIsICJjb21wYW55X2lkIjogIjY2OTk4NmYwMzM1YWQwNDI3ZTVmNTdlMyIsICJpbmRleCI6IG51bGwsICJ0eXBlIjogImFydGljbGUifQ==]{width="100%" height="300px"}", "image": ["https://images.tely.ai/telyai/eyvmppxa-this-mindmap-illustrates-the-essential-roles-of-ethics-committees-in-clinical-trials-start-at-the-center-with-the-main-role-then-follow-the-branches-to-see-each-specific-function-and-its-importance-in-ensuring-ethical-standards-and-participant-safety.webp", "https://images.tely.ai/telyai/dwholqnu-this-flowchart-outlines-the-steps-needed-to-obtain-ethics-committee-approval-for-clinical-trials-in-brazil-each-box-represents-a-key-step-in-the-process-and-the-arrows-show-the-order-in-which-these-steps-should-be-completed-follow-the-flow-to-understand-how-to-navigate-the-regulatory-landscape-effectively.webp", "https://images.tely.ai/telyai/lmoybooh-this-flowchart-shows-the-steps-you-need-to-take-to-get-approval-for-a-clinical-trial-in-brazil-start-at-the-top-and-follow-the-arrows-down-to-see-what-you-need-to-do-at-each-stage-including-what-documents-to-prepare-and-where-to-submit-them.webp", "https://images.tely.ai/telyai/ijcsaudr-each-box-represents-a-challenge-faced-during-the-approval-process-and-the-arrows-lead-to-strategies-that-can-help-overcome-these-challenges-follow-the-flow-to-see-how-to-tackle-each-obstacle-effectively.webp"], "inLanguage": "en", "author": {"@type": "Organization", "name": "bioaccess®"}, "publisher": {"@type": "Organization", "name": "bioaccess®", "url": "https://bioaccessla.com"}}</script>

  • Radiopharmaceutical Trial Logistics In Latin America: A Sponsor’s Playbook For Isotope Supply And Shipment Risk

    Radiopharmaceutical Trial Logistics in Latin America: A Sponsor’s Playbook for Isotope Supply and Shipment Risk

    Radiopharmaceutical trials can deliver decisive evidence quickly—but only if the isotope and drug product arrive exactly when the protocol needs them. In Latin America, sponsors often underestimate how much logistics determines whether a nuclear medicine study stays on schedule.

    This playbook explains how to plan radiopharmaceutical clinical trial logistics in Latin America: how to think about isotope supply constraints, how shipment rules affect scheduling, and what operational controls reduce risk across countries and sites.

    1) Why radiopharmaceutical logistics behave differently than “regular” clinical supply

    Radiopharmaceutical supply chains are shaped by physics and regulation. Short half-lives compress the delivery window, and transport is governed by dangerous-goods rules that require correct classification, packaging, labeling, and documentation. Air carriers may impose stricter acceptance policies than the baseline regulations, meaning a shipment can be rejected even if it is “technically compliant.”

    For sponsors, this means two things: (1) the critical path is often the shipment acceptance process, not the manufacturing step, and (2) your protocol schedule needs built-in flexibility for shipping windows.

    2) Build your “isotope availability model” before you lock the protocol calendar

    Before finalizing visit schedules, sponsors should map isotope availability and constraints:

    • Production modality: reactor-produced vs cyclotron-produced isotopes have different outage risks and distribution footprints.
    • Lane feasibility: direct flights vs multi-leg routes; the more handoffs, the higher the probability of delay.
    • Site readiness: receiving procedures, radiation safety officer availability, and hot-lab capacity.
    • Redundancy: secondary suppliers and alternative lanes that can be activated quickly.

    In practice, the sponsor’s goal is to convert “isotope risk” into a schedule plan: identify which visits require exact timing and where windows can be widened without compromising scientific validity.

    3) Shipment acceptance: treat documentation as a quality system, not paperwork

    Dangerous-goods air shipment requirements are aligned to international aviation technical instructions, but real-world acceptance depends on flawless execution: correct hazard classification, compliant packaging, correct labels/markings, and validated shipping papers. Forwarders commonly perform a regulation check and documentation validation step before a carrier will accept the booking, and carriers may refuse certain dangerous goods categories or require pre-approval.

    Operational best practices include:

    • Standardize templates for shipping papers and site receiving logs.
    • Pre-clear with carriers and confirm acceptance policies before the shipment arrives at the warehouse.
    • Run a “dry run” shipment simulation (without active product) to validate lane timing, broker actions, and site receipt workflow.
    • Define handoff accountability at every step: manufacturer → forwarder → airline → customs broker → site.

    These controls reduce last-minute rejections and help sponsors avoid protocol deviations caused by delayed dosing or imaging windows.

    4) Latin America-specific risk: cross-border variability and limited buffer time

    Latin American operations add variability because requirements and infrastructure differ across countries and even across airports. Two practical implications matter most:

    • Customs and clearance variability. A lane that works smoothly in one country may be unpredictable in another unless the broker has deep experience with radioactive/dangerous goods.
    • Limited buffer time. Short half-lives reduce your ability to absorb delays; redundancy becomes essential (backup flight options, backup production, and backup sites).

    When designing the operational plan, sponsors should assume that a percentage of shipments will be disrupted and proactively decide what happens next: reschedule patient, switch site, switch lane, or activate an alternate supplier.

    FAQ

    • What is the single biggest operational mistake in radiopharmaceutical trials?
      Locking a tight protocol schedule before validating the end-to-end shipment acceptance process and lane reliability.
    • How do dangerous-goods rules affect clinical trial timelines?
      They introduce additional steps—classification checks, packaging/labeling verification, documentation validation, and carrier pre-approval—that can determine whether shipments move as planned.
    • How can sponsors de-risk isotope supply in Latin America?
      Build redundancy (secondary suppliers and lanes), standardize documentation, pre-clear carriers, and validate site receiving readiness with a dry run.

    Bottom line: Radiopharmaceutical trials in Latin America succeed when sponsors operationalize logistics as part of the study design—aligning isotope availability, carrier acceptance, and site readiness with the protocol calendar.

    Sources referenced for general dangerous-goods shipment context: The overview of IATA DGR alignment to ICAO technical instructions and common shipment acceptance steps is summarized from a freight-forwarder explainer (Dimerco) and a dangerous-goods primer noting radioactive materials as Class 7 (EV Cargo).

  • Radiopharmaceutical Clinical Trials in Latin America: A Logistics Playbook for Isotope-Dependent Studies

    Radiopharmaceutical Clinical Trials in Latin America: A Logistics Playbook for Isotope-Dependent Studies

    Radiopharmaceutical clinical trials are different. Even when the science is strong and the protocol is clean, programs can fail due to a reality that traditional device or drug teams underestimate: your investigational product expires—fast. That makes logistics, importation planning, and site readiness mission-critical.

    Latin America offers compelling advantages for early-stage clinical research—experienced investigators, diverse patient populations, and often faster activation pathways. But isotope-dependent studies add unique constraints across borders, airports, customs processes, and nuclear medicine infrastructure. This article provides a sponsor-oriented playbook to design a radiopharmaceutical logistics system that supports protocol execution across Latin America.

    1) Start with the “half-life reality” and build the trial around it

    Radiopharmaceutical programs must align manufacturing, release, transport, and administration to the isotope’s half-life and imaging or therapeutic window. The practical implication is that clinical operations should be designed from the logistics backward—not from the protocol forward.

    • Define the maximum allowable time (MAT): The maximum time from end-of-synthesis to administration that still meets dose and quality criteria.
    • Translate MAT into route constraints: Which airports, flight schedules, and ground transport windows can reliably meet MAT?
    • Choose sites accordingly: A great investigator is not enough if a site is two unreliable connections away from the arrival airport.

    2) Build a supply strategy: local production, regional hubs, or cross-border shipment

    Most sponsors consider three models, sometimes combined:

    • Local production: Cyclotron or generator-based production inside the country, reducing border risk.
    • Regional hub: Manufacturing in one country with shipments to nearby countries where timing is feasible.
    • Cross-border shipment: Central manufacturing with direct shipment to sites, often higher operational risk for short half-life isotopes.

    Decision drivers: isotope half-life, batch release requirements, frequency of dosing/imaging, customs reliability, and the maturity of nuclear medicine infrastructure.

    3) Customs, permits, and paperwork: treat them as a core workstream

    Unlike many conventional clinical programs, radiopharmaceutical shipments can require coordination across multiple authorities (health, customs, transport, and sometimes nuclear or radiation safety regulators). Paperwork failures are not “minor admin issues”—they can destroy a batch.

    A practical sponsor approach:

    • Create a country-specific import dossier: A standardized pack containing product description, safety documentation, shipping classification, and required permits.
    • Pre-align with your logistics partner: Ensure they can manage controlled substances/radiation shipments and have airport-level handling experience.
    • Plan for documentation constraints: Some submission systems impose file size and formatting limitations, which can impact how you structure supporting documents.

    Risk mitigation: Maintain “pre-cleared” templates for invoices, certificates, and chain-of-custody records so each shipment is not a new negotiation.

    4) Cold chain and handoffs: map every minute and every signature

    Radiopharmaceutical trials require high integrity across handoffs—manufacturing release, airport handling, courier transfer, hospital receiving, radiopharmacy preparation (if applicable), and administration.

    • Define temperature and shielding requirements: Include validated packaging and monitoring devices.
    • Use chain-of-custody records: Document each transfer with time stamps and responsible parties.
    • Plan for failed deliveries: What happens if a flight is canceled? If customs holds the shipment? If the site cannot dose a patient that day?

    For short half-life isotopes, it may be more realistic to design protocols with flexible scheduling windows and backup dosing slots rather than a single “perfect” appointment that collapses with one delay.

    5) Site readiness: nuclear medicine capability is necessary but not sufficient

    Sites should be evaluated against operational capabilities that directly influence shipment success:

    • Receiving readiness: Can the site receive shipments after hours? Who signs? Where is the secure holding area?
    • Radiation safety workflow: Disposal, contamination procedures, monitoring, and staff training documentation.
    • Imaging/therapy coordination: Scanner availability, staffing schedules, and patient flow.
    • Contingency operations: Can the site reschedule quickly if dosing slips by hours?

    Operational best practice: Run a “dry rehearsal” shipment to test handoffs, documentation, and receiving steps before the first patient.

    6) Design a sponsor control tower for isotope-dependent trials

    Because time is the critical resource, sponsors benefit from a simple control tower model:

    • Shipment tracker: One dashboard for synthesis time, release, airport departure/arrival, customs status, courier pickup, and site receipt.
    • Rapid decision protocol: A predefined decision tree for whether to proceed, reroute, or cancel based on delay thresholds.
    • Communications cadence: Clear check-in times with manufacturing, courier, and site staff during dosing days.

    This structure reduces last-minute improvisation and helps teams learn systematically from each shipment cycle.

    FAQ: Radiopharmaceutical trial logistics in Latin America

    1) What is the single biggest logistics risk for short half-life isotopes?

    Border and airport unpredictability. A delay of hours can materially reduce dose viability, making preplanned routes and contingency options essential.

    2) Should we prioritize local production even if it is more expensive?

    Sometimes yes. Local production can reduce cross-border risk and improve dosing reliability, which may be more valuable than cost savings when early data is the goal.

    3) How can sponsors reduce failed dosing days?

    By selecting sites near reliable arrival points, rehearsing end-to-end shipments, maintaining documentation templates, and using a control tower to manage real-time decisions.

    Conclusion: Radiopharmaceutical trials can be executed successfully in Latin America, but they require a logistics-first mindset. Build your protocol around half-life constraints, treat customs as a core workstream, and operate a shipment control tower. When logistics is engineered as a system—not handled as an afterthought—sponsors gain the reliability needed to generate high-quality clinical data on schedule.

  • Argentina’s $8 Billion Clinical Research Commitment: What It Means For Medtech Startup FIH Trials In 2026

    Argentina’s $8 Billion Clinical Research Commitment: What It Means for MedTech Startup FIH Trials in 2026

    By Julio Martinez-Clark, CEO, bioaccess® | June 2026

    The Signal That Most MedTech Founders Missed

    In late May 2026, seven of the world’s largest pharmaceutical companies — Pfizer, Merck, Roche, Novartis, Bristol Myers Squibb, GSK, and Sanofi — pledged a combined $8 billion in Argentine clinical research investment over the 2026–2032 period. Days later, Argentina’s national drug and food regulator, ANMAT, published Disposición 2978/2026, cutting import tariffs on medicines and medical devices by 50 to 70 percent, effective June 1, 2026.

    The pharma industry picked up the $8 billion figure immediately. MedTech largely did not. That gap is worth examining — because for a structural heart, neuromodulation, or radiopharmaceuticals startup planning a first-in-human (FIH) trial in the next 18 months, these two policy events together represent one of the most significant shifts in the LATAM early-phase clinical research environment in a decade.

    This piece walks through what actually changed, why it matters specifically for device and biotech FIH programs, and how to think about Argentina as part of a first-in-human trial site strategy in 2026.

    What Changed: Disposición 2978/2026 and the $8B Commitment

    The Tariff Reduction

    Disposición 2978/2026 is not a pilot, a phase-in, or a proposed amendment — it is in effect. Import tariffs on medicines and medical devices were reduced by 50 to 70 percent, effective June 1, 2026. For a device company running an FIH feasibility study, this has a direct, calculable effect on budget: investigational devices entering Argentina for clinical use carry materially lower landed cost.

    In early-phase device trials, the investigational product is often the single largest variable cost item outside of site and monitoring fees. A 50 percent reduction in import tariffs on a novel transcatheter device, for example, can change the per-patient cost model meaningfully — particularly for seed-stage and Series A sponsors working with sub-$15 million clinical trial budgets.

    The tariff change also simplifies regulatory logistics. One of the historically cited friction points in Argentine FIH trials has been the import authorization process for investigational devices that were not commercially registered in Argentina. Lower tariff classification, combined with ANMAT’s active throughput cadence, reduces one layer of that friction.

    The $8 Billion Pharma Commitment

    The $8 billion multi-company pledge is not a single infrastructure project — it represents committed clinical research spend across seven major sponsors over six years. The practical implications:

    • Site infrastructure: When Pfizer, Roche, and Novartis are committing multi-year research spend to Argentina, they are investing in investigator networks, clinical infrastructure, and regulatory capacity at sites. This infrastructure — trained investigators, GCP-compliant facilities, ethics committees with high-volume experience — is precisely what a MedTech startup needs for an FIH feasibility study.
    • Regulatory capacity: ANMAT’s workload will increase, but so will its institutional capacity. Regulators that process high volumes of multi-national submissions develop faster, more predictable review cycles. Argentina approved 290 new clinical studies in 2025, an 8 percent year-over-year increase, with more than 1,000 active trials and 50,000+ participants enrolled. The $8 billion commitment is a signal that this trajectory accelerates.
    • International credibility: Large pharma’s visible commitment to Argentina as a clinical research destination reduces the country risk perception that smaller device sponsors sometimes encounter when presenting LATAM FIH data to US investors and regulatory reviewers.

    Practical Considerations for MedTech Sponsors

    A realistic timeline from engagement to first patient for a novel device FIH study in Argentina: Weeks 1–4 site identification; Weeks 5–8 ethics committee; Weeks 6–12 ANMAT authorization; Weeks 10–16 site initiation; Weeks 14–20 first patient in. The Argentina FIH environment also benefits from bioaccess® multi-country capability covering Argentina and Colombia as primary FIH jurisdictions.

    Sources

  • 10 Insights on Alpha-Era Radiopharmaceuticals Clinical Trials

    10 Insights on Alpha-Era Radiopharmaceuticals Clinical Trials

    Introduction

    The landscape of radiopharmaceutical clinical trials is experiencing a remarkable transformation, particularly with the rise of alpha-era therapies that are set to redefine treatment protocols. Organizations like bioaccess® are at the forefront of this evolution in Latin America, streamlining the trial process and leveraging the region’s unique regulatory advantages. However, as the demand for innovative therapies escalates, so do the challenges surrounding patient recruitment, regulatory compliance, and logistical management.

    How can stakeholders effectively navigate these complexities to fully harness the potential of alpha-emitting radiopharmaceuticals and ensure successful outcomes in clinical research?

    This pivotal moment in the Medtech landscape underscores the importance of collaboration and strategic action. Bioaccess® is not just addressing these challenges; they are paving the way for a new era of clinical research. By focusing on innovative solutions and fostering partnerships, they are enhancing the efficiency of clinical trials and improving patient access to groundbreaking therapies.

    As we delve deeper into this topic, consider how these developments might impact your own clinical research endeavors.

    bioaccess: Pioneering Clinical Trials for Radiopharmaceuticals in Latin America

    bioaccess® stands out as a leader in conducting across Latin America. With a robust network of over 50 pre-qualified research locations, the organization accelerates the study process, achieving . This swift turnaround is complemented by than those in the US and EU, a vital advantage considering the complex regulatory landscape and the urgent timelines tied to the short half-lives of isotopes used in radiopharmaceuticals.

    Industry leaders emphasize that prompt ethics approvals are crucial for maintaining the integrity and success of clinical studies, particularly in , reinforcing bioaccess®’s commitment to ethical standards. Moreover, Colombia offers significant , including a 100% tax deduction for investments in science, technology, and innovation projects, further enhancing the organization’s capabilities. By leveraging local knowledge and executing efficient procedures, bioaccess® not only facilitates positive outcomes in but also positions itself as a key player in the expanding in the region.

    The organization’s partnership with Caribbean Health Group aims to establish Barranquilla as a premier hub for medical studies in Latin America, with the backing of the Colombian Minister of Health. When compared to average ethics approval times in other regions, bioaccess®’s efficiency underscores its competitive edge in the market. This strategic positioning not only benefits the organization but also contributes to the broader landscape of .

    The central node represents bioaccess®'s role in clinical trials, while the branches show the various strengths and advantages that support this leadership. Each branch can be explored for more detailed information.

    Targeted Alpha Therapies: Transforming Radiopharmaceutical Clinical Trials

    are revolutionizing the field of radiopharmaceutical studies, offering powerful . By utilizing alpha-emitting isotopes, these therapies excel in treating localized tumors due to their limited radiation range. The integration of into research not only boosts therapeutic effectiveness but also aligns with the increasing focus on . This shift has led to a , underscoring their potential to significantly enhance outcomes for oncology patients.

    Notably, the is expected to expand from $1.03 billion in 2025 to $1.2 billion in 2026, and further to $2.25 billion by 2030. This growth is driven by and the adoption of . Successful medical studies have demonstrated improved responses among patients, with over 20 alpha therapies currently under investigation in alpha-era radiopharmaceuticals , showcasing the promising future of this innovative treatment method.

    With , researchers can enroll treatment-naive cardiology or neurology groups 50% faster than Western sites, achieving savings of $25K per patient with -no rework, no delays. Industry experts highlight that the features key players like Bayer and Novartis, who are actively involved in the development and commercialization of these therapies, alongside bioaccess®.

    The center represents the main topic, and the branches show different aspects of targeted alpha therapies. Each branch highlights important information, making it easy to understand how they relate to each other.

    Conducting in Latin America presents a unique set of challenges, primarily due to the complex . Each country has its own – imposing specific requirements for study approval. Understanding these regulations is not just important; it’s critical for ensuring compliance and expediting the approval process.

    Colombia stands out in this landscape, offering a particularly favorable . With compared to North America or Western Europe, the total IRB/EC and MoH (INVIMA) review process typically takes only 90-120 days. This efficiency is a game-changer for clinical research. Bioaccess® employs a strategic approach to , assisting clients in crafting customized strategies that align with local regulations. This not only reduces delays but also enhances the likelihood of successful outcomes.

    Moreover, , providing access to a population of over 50 million, with 95% covered by universal healthcare. This extensive coverage facilitates , making it an attractive option for clinical studies. Additionally, the nation offers , including a 100% tax deduction for investments in science, technology, and innovation initiatives. This combination of factors makes Colombia an appealing location for research studies, reinforcing the importance of collaboration in navigating the .

    The central node represents the main topic, while branches show different aspects of the regulatory landscape. Each color-coded branch helps you identify specific countries and their unique regulatory features, making it easier to understand the overall landscape.

    Effective Patient Recruitment Strategies for Radiopharmaceutical Trials

    demands of this field. To capture attention, it’s essential to recognize that successful methods include:

    1. Leveraging local networks
    2. Utilizing digital platforms to broaden outreach

    In fact, involving ; a striking 73% of individuals prefer to discover research opportunities through their doctor’s office.

    To build interest, employing and providing clear, comprehensive information about the benefits and risks of participation can significantly . By implementing these strategies, bioaccess® has accelerated , ensuring that studies meet their timelines and objectives. This proactive approach is vital, especially considering that roughly 80% of face delays or closures due to recruitment challenges.

    In conclusion, collaboration and . As we move forward, it’s imperative to consider how these insights can be applied to improve recruitment processes in .

    The central node represents the main topic, while the branches show different strategies. Each sub-branch provides additional details or statistics that support the main strategies, helping you understand how to improve patient recruitment.

    The Role of Early-Phase Research in Radiopharmaceutical Development

    Early-phase research is vital in developing radiopharmaceuticals, as it assesses the . These studies establish , enhance understanding of pharmacokinetics, and identify potential side effects, especially given the narrow therapeutic window often associated with radiopharmaceuticals. Notably, recent findings reveal that , which employ sub-therapeutic microdoses in small cohorts, can significantly reduce toxicology requirements. This approach provides earlier go/no-go clarity for , allowing researchers to confirm drug behavior in humans before committing substantial resources to .

    The objectives of encompass assessing biodistribution, target engagement, and , all crucial for refining development strategies. Integrating PET or SPECT imaging into these studies facilitates real-time visualization of drug distribution, yielding critical insights that inform subsequent phases. However, it’s essential to recognize that do not focus on traditional safety or efficacy testing; rather, they aim to confirm whether a drug behaves in humans as anticipated.

    Operational challenges in executing necessitate meticulous logistical and procedural planning, often underestimated by sponsors. Addressing these logistical elements early can prevent costly rework and ensure data integrity.

    The platform plays a pivotal role in facilitating these by providing comprehensive support, including and site management. By leveraging its global network of expedited clinical research locations, the organization accelerates approval procedures by up to 40% and reduces expenses by 30%, helping to overcome regulatory hurdles that frequently challenge startups. This commitment ensures that experiments yield high-quality data, ultimately enhancing the likelihood of successful market entry in Latin America’s rapidly growing . With a focus on operational excellence, bioaccess® , ensuring compliance with regulatory expectations and optimizing study outcomes.

    Each box represents a step in the research process. Follow the arrows to see how each stage connects and leads to the next, with objectives highlighted to show what each phase aims to achieve.

    Integrating Theranostics into Radiopharmaceutical Clinical Trials

    Integrating theranostics into alpha-era represents a pivotal advancement in . This innovative approach merges diagnostic imaging with , allowing for of treatment effectiveness. Such capability enables prompt adjustments based on individual responses, enhancing the precision of radiopharmaceutical therapies and significantly .

    Studies have shown that individuals receiving theranostic treatments experience higher response rates and improved overall survival compared to traditional therapies. This integration serves a crucial function, enabling alpha-era that employ theranostic strategies to enhance treatment pathways. With a focus on ensuring that patients receive the most effective therapies tailored to their specific needs, this entity stands at the forefront of this innovative approach, driving across Latin America.

    As we look to the future, collaboration among stakeholders in the Medtech landscape will be essential to address key challenges and optimize these treatment methodologies. The commitment to integrating theranostics not only reflects a significant leap forward in cancer care but also underscores the importance of in improving patient outcomes.

    The center shows the main topic, and the branches illustrate the benefits and future directions of integrating theranostics into clinical trials. Each branch highlights important aspects that contribute to improving cancer care.

    Logistical Considerations for Short-Lived Radioisotope Trials

    Carrying out experiments with short-lived radioisotopes presents significant that demand meticulous management. These isotopes, with half-lives ranging from mere minutes to several hours, require precise timing for their production, transportation, and administration. To address these challenges effectively, the company employs that ensure prompt and secure delivery of radioisotopes to testing locations. This includes:

    These strategies greatly enhance operational efficiency.

    Moreover, the organization’s innovative approach allows for the inclusion of 50% faster than their Western counterparts, resulting in with -no rework, no delays. By prioritizing these logistical factors and leveraging , the organization minimizes delays and guarantees that individuals receive their treatments as planned. This ultimately supports the success of alpha-era radiopharmaceuticals , highlighting the critical role of collaboration in overcoming challenges in clinical research.

    Follow the arrows to see how each logistical strategy connects and contributes to the success of the trials. Each box represents a key step in the process, helping you understand how the organization manages these complex logistics.

    Collaborating with Local Research Sites for Successful Trials

    Collaboration with local research sites stands as a cornerstone of successful in Latin America. By partnering with established platforms that possess in-depth knowledge of local clientele demographics and regulatory frameworks, bioaccess® significantly enhances study efficiency and . These streamline research operations, from participant recruitment to , ensuring compliance with local regulations.

    Notably, studies that leverage achieve , with demonstrating a 40% faster enrollment compared to traditional methods. Furthermore, an impressive 93.6% of individuals with chronic conditions express the importance of understanding that they can complete the entire study, highlighting the critical role of local engagement strategies tailored to individual needs. , including a 30% cost savings relative to North America and Western Europe, a regulatory review process that spans only 90-120 days, and a healthcare system ranked among the best globally, further strengthen these initiatives.

    Additionally, local sites often have established connections with healthcare providers, which can and improve patient retention throughout the study. The partnership between bioaccess™ and Caribbean Health Group aims to position Barranquilla as a leading research hub in Latin America, supported by the Colombian Minister of Health, thereby reinforcing the effectiveness of these .

    The central node represents the main topic of collaboration, while the branches show the various benefits and statistics that support the importance of local partnerships in research.

    Ensuring Data Quality and Regulatory Compliance in Trials

    In the realm of radiopharmaceutical studies, the importance of data quality and cannot be overstated. Bioaccess® implements rigorous that align with , ensuring that all information gathered during studies is accurate, reliable, and compliant with regulatory standards. This commitment includes:

    1. Conducting
    2. Selecting suitable research sites
    3. Providing regular audits
    4. Comprehensive training for site staff
    5. Utilizing advanced data management systems to streamline data collection and analysis

    The evolving role of is pivotal in this landscape. They must adapt to new technologies and engage in ongoing training to stay current with GCP guidelines. Addressing the high turnover rates among CRCs is essential, as this can significantly impact the progress of research studies. By prioritizing and leveraging its extensive management services, bioaccess® not only enhances the credibility of research results but also fosters trust with regulatory authorities and stakeholders.

    The central node represents the main focus on data quality and compliance, while the branches show the specific practices and roles that support this goal. Each branch helps illustrate how these elements work together to enhance research credibility.

    The future of alpha-era radiopharmaceuticals is on the brink of remarkable advancements, driven by technological innovations, regulatory reforms, and a heightened focus on . This evolution is not just a trend; it’s a transformation that demands attention. Key developments include:

    1. The integration of , which are revolutionizing study designs and enhancing .
    2. AI-driven models that expedite the identification of novel compounds, significantly cutting down research time and costs.

    Moreover, the increasing emphasis on – holds the promise of improving treatment precision and outcomes for patients. As the radiopharmaceutical field evolves, our company is dedicated to steering innovations in alpha-era radiopharmaceuticals , ensuring that clients can adeptly navigate the complexities of this dynamic research landscape. For instance, treatment-naive cardiology or neurology groups can be enrolled 50% faster than their Western counterparts, translating to savings of $25K per patient with .

    In addition, bioaccess® offers comprehensive , encompassing:

    • Feasibility studies
    • Site selection
    • Compliance reviews
    • Trial setup
    • Import permits
    • Project management
    • Reporting

    Looking ahead, hospitals are projected to capture 47.7% of the , underscoring the growing significance of these innovations in clinical settings. This is not just a statistic; it’s a to engage with these advancements and collaborate for a brighter future in clinical research.

    The central node represents the main topic, while the branches show key developments and services. Each color-coded branch helps you quickly identify different areas of focus in the evolving landscape of radiopharmaceuticals.

    Conclusion

    The exploration of alpha-era radiopharmaceuticals clinical trials reveals a landscape marked by innovative therapies, strategic collaborations, and regulatory advancements. Organizations like bioaccess® are leading the charge, utilizing their extensive networks and expertise to navigate the complexities of clinical research in Latin America. This commitment not only accelerates approval processes but also enhances patient outcomes through targeted therapies and efficient recruitment strategies.

    Key insights include:

    • The rapid ethics approval times in Colombia
    • The rise of targeted alpha therapies
    • The critical integration of theranostics into treatment protocols

    Additionally, the logistical challenges posed by short-lived radioisotopes and the necessity for robust local partnerships are emphasized as vital factors influencing the success of clinical trials. Addressing these elements clearly indicates the potential for improved patient care and significant advancements in cancer treatment.

    Looking ahead, the future of radiopharmaceutical clinical trials is set for remarkable growth, driven by technological innovations and a focus on personalized medicine. Stakeholders must embrace these developments and collaborate effectively, ensuring that the promise of alpha-era therapies translates into tangible benefits for patients and the broader healthcare community. Engaging with these insights will not only enhance research outcomes but also pave the way for transformative advancements in cancer care across Latin America and beyond.

    Frequently Asked Questions

    What is bioaccess® and what role does it play in clinical trials for radiopharmaceuticals in Latin America?

    Bioaccess® is a leader in conducting alpha-era radiopharmaceuticals clinical trials across Latin America, utilizing a network of over 50 pre-qualified research locations to accelerate study processes and achieve ethics approvals in 4-8 weeks.

    How does bioaccess®’s patient enrollment rate compare to that in the US and EU?

    Bioaccess® achieves patient enrollment rates that are 40% faster than those in the US and EU, which is crucial given the short half-lives of isotopes used in radiopharmaceuticals.

    What are the advantages of conducting clinical trials in Colombia?

    Colombia offers significant R&D tax incentives, such as a 100% tax deduction for investments in science, technology, and innovation projects, along with a favorable regulatory environment that allows for quicker ethics approvals and patient recruitment.

    What are targeted alpha therapies and why are they important in radiopharmaceutical studies?

    Targeted alpha therapies utilize alpha-emitting isotopes to treat localized tumors with minimal damage to healthy tissues. They enhance therapeutic effectiveness and align with the focus on precision medicine, leading to increased funding and attention in the field.

    What is the projected growth of the targeted alpha-therapy market?

    The targeted alpha-therapy market is expected to expand from $1.03 billion in 2025 to $1.2 billion in 2026, and further to $2.25 billion by 2030, driven by advancements in isotope manufacturing and personalized radiotherapy.

    How does bioaccess® assist clients in navigating regulatory challenges in Latin America?

    Bioaccess® employs a strategic approach to regulatory consulting, helping clients craft customized strategies that align with local regulations, which reduces delays and enhances the likelihood of successful outcomes.

    What is the typical timeline for the IRB/EC and MoH review process in Colombia?

    The review process in Colombia typically takes only 90-120 days, which is significantly more efficient compared to North America or Western Europe.

    What is the healthcare coverage like in Colombia for clinical trial participants?

    Colombia’s healthcare system is among the best in Latin America, providing access to over 50 million people, with 95% of the population covered by universal healthcare, facilitating patient recruitment for clinical studies.

    List of Sources

    1. bioaccess: Pioneering Clinical Trials for Radiopharmaceuticals in Latin America
      • linkedin.com (https://linkedin.com/pulse/latin-america-clinical-trials-boom-462b-2025-794b-2034-iaqhc)
      • todayinsci.com (https://todayinsci.com/QuotationsCategories/E_Cat/Ethics-Quotations.htm)
      • Latin America Clinical Trials Market Size & Outlook, 2033 (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/latin-america)
      • nclusiv.co.uk (https://nclusiv.co.uk/edi-consulting/f/patient-engagement-quotes-for-every-purpose-audience)
      • towardshealthcare.com (https://towardshealthcare.com/insights/latin-america-clinical-trials-market-sizing)
    2. Targeted Alpha Therapies: Transforming Radiopharmaceutical Clinical Trials
      • uclahealth.org (https://uclahealth.org/news/release/ucla-health-launches-novel-clinical-trial-recurrent-prostate)
      • clinicaltrialvanguard.com (https://clinicaltrialvanguard.com/news/targeted-alpha-therapy-clinical-trials-an-overview)
      • thebusinessresearchcompany.com (https://thebusinessresearchcompany.com/report/targeted-alpha-therapy-global-market-report)
      • targetedonc.com (https://targetedonc.com/view/antitumor-activity-seen-with-targeted-alpha-therapy-212pb-vmt—net-in-sstr2-nets)
    3. Navigating Regulatory Challenges in Latin American Clinical Trials
      • clinicaltrialsarena.com (https://clinicaltrialsarena.com/news/can-regulatory-reform-unearth-latams-untapped-potential-for-drug-development)
      • Life Sciences — In Focus: Navigating The Regulatory Landscape – Latin America Edition (https://vistatec.com/life-sciencesin-focus-navigating-the-regulatory-landscape-latin-america-edition)
      • juliomartinezclark.com (https://juliomartinezclark.com/blog/first-in-human-clinical-trials-latin-america-complete-guide)
      • bioaccessla.com (https://bioaccessla.com/blog/understanding-regulatory-requirements-for-latin-america-trials-a-comprehensive-overview-of-regulatory-requirements-for-latin-america-trials)
      • Checking your browser – reCAPTCHA (https://pmc.ncbi.nlm.nih.gov/articles/PMC11361337)
    4. Effective Patient Recruitment Strategies for Radiopharmaceutical Trials
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • 10 Inspiring Patient Experience Quotes | Relias (https://relias.com/blog/patient-experience-quotes)
      • onestudyteam.com (https://onestudyteam.com/blog/clinical-trial-metrics-to-evaluate-patient-recruitment-campaigns)
      • Considerations For Improving Patient Recruitment Into Clinical Trials (https://clinicalleader.com/doc/considerations-for-improving-patient-0001)
      • 10 Patient Experience Quotes for Inspiration (https://carecloud.com/continuum/patient-experience-quotes-for-inspiration)
    5. The Role of Early-Phase Research in Radiopharmaceutical Development
      • thebrackengroup.com (https://thebrackengroup.com/blog/phase-zero-studies-in-radiopharmaceutical-development-an-early-pathway-to-insight)
    6. Integrating Theranostics into Radiopharmaceutical Clinical Trials
      • syneoshealth.com (https://syneoshealth.com/insights-hub/theranostics-trials-oncology-essential-capabilities-sponsors)
    7. Logistical Considerations for Short-Lived Radioisotope Trials
      • contractpharma.com (https://contractpharma.com/exclusives/the-strategic-advantage-of-precision-in-radiopharmaceutical-logistics)
    8. Collaborating with Local Research Sites for Successful Trials
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • crn-global.com (https://crn-global.com/engaging-communities-the-value-of-local-research-sites-in-clinical-trials)
      • 6 Benefits of Clinical Research Collaboration and Partnerships (https://vccrn.org/benefits-clinical-research-collaboration-and-partnerships)
      • myscrs.org (https://myscrs.org/resources/patient-recruitment-landscape)
      • sironclinical.com (https://sironclinical.com/clinical-trial-success-depends-on-strong-partnerships-heres-why)
    9. Ensuring Data Quality and Regulatory Compliance in Trials
      • Sponsor-Level Compliance with ClinicalTrials.gov Reporting Requirements: A Comprehensive Analysis (https://publichealth.realclearjournals.org/research-articles/2025/09/sponsor-level-compliance-with-clinicaltrials-gov-reporting-requirements-a-comprehensive-analysis)
      • precisionformedicine.com (https://precisionformedicine.com/blog/case-study-streamlining-radiopharmaceutical-clinical-trials)
      • Regulatory Compliance in Clinical Trials | CCRPS (https://ccrps.org/clinical-research-blog/regulatory-compliance-in-clinical-trials-what-you-need-to-know)
      • acceldata.io (https://acceldata.io/blog/a-comprehensive-guide-to-data-quality-governance-in-pharmaceuticals)
    10. Future Trends in Radiopharmaceutical Clinical Trials
    • 10 Insights from Healthcare Innovators: The Best Quotes from the ‘Leader to Leader’ Podcast in 2024 – Healthcare IT Leaders (https://healthcareitleaders.com/blog/insights-from-healthcare-innovators)
    • straitsresearch.com (https://straitsresearch.com/report/radiopharmaceutical-market)
    • rootsanalysis.com (https://rootsanalysis.com/reports/radiopharmaceuticals-market.html)
    • linkedin.com (https://linkedin.com/posts/drlk_himss-2025-day-1-top-insights-activity-7302803308383981568-DcHp)
    • nordicglobal.com (https://nordicglobal.com/blog/9-insightful-quotes-on-cloud-and-ai-from-stanford-health-care-and-aws-leaders-at-arab-health-2024)